[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account
Search By NCT Number
Search By Keyword
Genetics & Targets
Phases
Primary Purpose
Country
State
Showing 572 trials matching your filters.
A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractor...
This study is a Phase II single-center clinical trial designed to assess the efficacy, safety, and tolerability of pembrolizumab in combination with the 7-day regimen of azacitidine for the treatment of relapsed/refractory HL.

DRUG: Azacytidine

DRUG: Pembrolizumab

CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)
This study is for patients who have lymphoma or leukemia that has come back or has not gone away after treatment. Because there is no standard treatment for this cancer, patients are being asked to volunteer for a gene transfer research study using s...

GENETIC: CD19.CAR-aNKT cells

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction Wi...
The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma. Immune system cells (such as NK cells) are made...

DRUG: Cyclophosphamide

DRUG: CAR.70/IL15-transduced CB-NK cells

DRUG: Fludarabine phosphate

Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies
This study is a multi-center study to evaluate the safety of KUR-502 in subjects with refractory/relapsed B-cell NHL or leukemia (ALL or CLL).

GENETIC: KUR-502

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refra...
This phase I trial studies the side effects and best dose of palbociclib when given alone and in combination with sorafenib, decitabine, or dexamethasone in treating patients with leukemia that has come back (recurrent) or that does not respond to pr...

DRUG: Decitabine

DRUG: Dexamethasone

DRUG: Palbociclib

DRUG: Sorafenib

Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma
This is an international, first-in-human, multicenter, open-label Phase 1/2 study to evaluate the safety profile, tolerability of IPH6501, and determine the recommended phase 2 dose (RP2D) for patients with B-Cell non-Hodgkin lymphoma.

DRUG: IPH6501

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituxi...
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma or NHL). This study will be made up of ...

DRUG: Odronextamab

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Prednisone/prednisolone

DRUG: Bendamustine

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Ly...
Researchers are looking for new ways to treat people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are types of blood cancer. Researchers want to know if people who take nemtabrutinib compared to those who t...

DRUG: Nemtabrutinib

DRUG: Fludarabine

DRUG: Cyclophosphamide

DRUG: Bendamustine

BIOLOGICAL: Rituximab

BIOLOGICAL: Truxima

BIOLOGICAL: Ruxience

BIOLOGICAL: Riabni

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relaps...
The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrutinib plus v...

DRUG: Nemtabrutinib

DRUG: Venetoclax

BIOLOGICAL: Rituximab

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B...
This phase II trial studies the safety and how well of loncastuximab tesirine when given together with mosunetuzumab works in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refract...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

BIOLOGICAL: Loncastuximab Tesirine

BIOLOGICAL: Mosunetuzumab

PROCEDURE: Positron Emission Tomography

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refrac...
This is a single-center, nonrandomized, open-label dose-escalation study followed by dose-expansion of CD19- CD34t metabolically programmed CAR T-cell therapy in adult patients with relapsed or refractory CD19 B-cell non-Hodgkin lymphoma (NHL) or chr...

DRUG: Cyclophosphamide injection

DRUG: Fludarabine Injection

BIOLOGICAL: CD19-CD34t metabolically programmed CAR transduced T-cells

Mevrometostat Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Folli...
A Phase 1 Dose Escalation and Expanded Cohort Study Of PF-06821497 (Mevrometostat) in Adult Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) And Follicular Lymphoma (FL).

DRUG: Mervometostat (PF-06821497)

DRUG: Enzalutamide

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults...
This phase II trial studies how well naive T-cell depletion works in preventing chronic graft-versus-host disease in children and young adults with blood cancers undergoing donor stem cell transplant. Sometimes the transplanted white blood cells from...

RADIATION: Total-Body Irradiation

DRUG: Thiotepa

DRUG: Fludarabine

DRUG: Cyclophosphamide

DRUG: Busulfan

PROCEDURE: Allogeneic Bone Marrow Transplantation

DRUG: Tacrolimus

DRUG: Methotrexate

PROCEDURE: Naive T Cell-Depleted Hematopoietic Stem Cell Transplantation

PROCEDURE: Echocardiography

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relaps...
The body has different ways of fighting infection and disease. No single way is effective at fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are proteins that protect the body f...

BIOLOGICAL: iC9-CAR19 cells

DRUG: Rimiducid

DRUG: Cyclophosphamide

DRUG: Fludarabine

Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia
This phase II trial investigates the how well acalabrutinib and obinutuzumab work in treating patients with chronic lymphocytic leukemia (CLL). Acalabrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. I...

DRUG: Acalabrutinib

BIOLOGICAL: Obinutuzumab

Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies
The purpose of this study is to determine if it is possible to treat relapsed or refractory lymphoid malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia) with a new type of T cell-based immunotherapy (therap...

BIOLOGICAL: Fully human anti CD19 CAR-T Cell Dose

DRUG: Fludarabine

DRUG: Cyclophosphamide

A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comp...
This study will evaluate the efficacy and safety of mosunetuzumab in combination with lenalidomide (M + Len) compared to rituximab in combination with lenalidomide (R + Len) in participants with relapsed or refractory (R/R) follicular lymphoma (FL) w...

DRUG: Mosunetuzumab

DRUG: Lenalidomide

DRUG: Rituximab

DRUG: Tociluzumab

Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Und...
This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therap...

DRUG: Fludarabine

RADIATION: Total-Body Irradiation

PROCEDURE: Donor Lymphocyte Infusion

DRUG: Cyclophosphamide

DRUG: Tacrolimus

DRUG: Mycophenolate Mofetil

PROCEDURE: Hematopoietic Cell Transplantation

DRUG: Melphalan

PROCEDURE: Bone Marrow Aspiration and Biopsy

PROCEDURE: Diagnostic Imaging

PROCEDURE: Biospecimen Collection

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of D...
This phase I/II trial tests the safety of tafasitamab, retifanlimab, and rituximab (TRR) as a prephase treatment and in combination with standard therapy consisting off cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or polatuzumab ...

PROCEDURE: Bone Marrow Biopsy

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Prednisone

BIOLOGICAL: Retifanlimab

BIOLOGICAL: Rituximab and Hyaluronidase Human

BIOLOGICAL: Tafasitamab

DRUG: Vincristine

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Multigated Acquisition Scan

OTHER: Fludeoxyglucose F-18

PROCEDURE: Positron Emission Tomography

PROCEDURE: Computed Tomography

PROCEDURE: Biospecimen Collection

DRUG: Polatuzumab Vedotin

Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light
The goal of this clinical trial is to assess the benefit of continuous treatment with synthetic hypericin ointment (HyBryte) and visible light in patients with mycosis fungoides for up to 12 months (54 weeks). Funding Source: FDA OOPD.

DRUG: Hypericin

OTHER: Visible Light

Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukem...
This phase II trial tests whether the pneumococcal pneumonia vaccine series (PCV20 and PPSV23) works to mount an effective immune response in patients with chronic lymphocytic leukemia. PCV20 and PPSV23 are both vaccines that protect against bacteria...

BIOLOGICAL: Pneumococcal 20-valent Conjugate Vaccine

BIOLOGICAL: Pneumococcal Polyvalent Vaccine

OTHER: Questionnaire Administration

Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies
Background: Non-Hodgkin lymphomas are blood cancers that can be difficult to treat. They can also return after treatment. Examples include diffuse large B-cell lymphoma (DLBCL) and peripheral T-cell lymphoma (PTCL). More effective treatments are nee...

DEVICE: Vysis LSI MYC Break Apart Rearrangement Probe Kit

DRUG: venetoclax

DRUG: VIP152

DRUG: prednisone

Venetoclax Plus Inotuzumab for B-ALL
This research study is evaluating the safety and efficacy of administering venetoclax and inotuzumab ozogamicin in combination in patients with acute lymphoblastic leukemia (ALL) The names of the study drugs involved in this study are: * Venetoclax...

DRUG: Venetoclax

DRUG: Dexamethasone

DRUG: Inotuzumab Ozogamicin

Study of E7777 Prior to Kymriah for R/R DLBCL
This is a single institution Phase I study to determine the maximum tolerated dose (MTD) of E7777 when given prior to cyclophosphamide/fludarabine (CY/Flu) lymphodepletion (LD) chemotherapy and Kymriah, a commercial tisagenlecleucel product, for the ...

DRUG: E7777

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Age...
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants with relapsed or refractory non-Hodgkin's lymphomas.

DRUG: CC-99282

DRUG: Rituximab

DRUG: Obinutuzumab

DRUG: Tafasitamab

DRUG: Valemetostat

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell L...
This phase II trial studies the effect of extracorporeal photopheresis (ECP) and mogamulizumab in treating patients with erythrodermic cutaneous T cell lymphoma (CTCL), a type of skin lymphoma. CTCL is a rare type of cancer that begins in the white b...

PROCEDURE: Extracorporeal Photopheresis

BIOLOGICAL: Mogamulizumab

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase
This is a phase I/II clinical trial assessing the tolerability and efficacy of CM4620 in children and young adults with acute pancreatitis caused by asparaginase. The tolerability of CM4620 when given to patients receiving frontline chemotherapy will...

DRUG: CM4620

Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients o...
To learn if adding epcoritamab to the treatment combination R-miniCVP (rituximab, cyclophosphamide, vincristine, prednisone) can help to control newly diagnosed DLBCL. The safety of this combination will also be studied.

DRUG: Prednisone

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Vincristine

DRUG: Epcoritamab

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Unt...
This phase I trial studies the side effects of polatuzumab vedotin when given with combination chemotherapy with or without glofitamab for the treatment of patients with untreated large B-cell lymphoma that grows and spreads quickly and has severe sy...

DRUG: Polatuzumab Vedotin

BIOLOGICAL: Rituximab

DRUG: Prednisone

DRUG: Etoposide

DRUG: Doxorubicin

DRUG: Cyclophosphamide

BIOLOGICAL: Glofitamab

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Echocardiography

PROCEDURE: FDG-Positron Emission Tomography

PROCEDURE: Computed Tomography

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
This phase I trial studies the effects of CD-19 directed chimeric antigen receptor (CAR)-T cell therapy for the treatment of patients with B cell malignancies that have come back (recurrent) or have not responded to treatment (refractory). CD-19 CAR-...

BIOLOGICAL: Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563

DRUG: Bendamustine

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

DRUG: Fludarabine

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Positron Emission Tomography

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
In this study, the investigators are hypothesizing that daratumumab-hyaluronidase will effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment with chemotherapy.

DRUG: Daratumumab / Hyaluronidase Injection

DRUG: Daratumumab / Hyaluronidase Injection

DRUG: Daratumumab / Hyaluronidase Injection

DRUG: Daratumumab / Hyaluronidase Injection

Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphobla...
This phase I/II studies the side effects of pembrolizumab and blinatumomab and to see how well they work in treating participants with acute lymphoblastic leukemia that has come back or has not responded to the treatment. Monoclonal antibodies, such ...

BIOLOGICAL: Blinatumomab

OTHER: Laboratory Biomarker Analysis

BIOLOGICAL: Pembrolizumab

Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adol...
This phase III trial compares hematopoietic (stem) cell transplantation (HCT) using mismatched related donors (haploidentical \[haplo\]) versus matched unrelated donors (MUD) in treating children, adolescents, and young adults with acute leukemia or ...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

DRUG: Busulfan

DRUG: Cyclophosphamide

PROCEDURE: Echocardiography

DRUG: Fludarabine

PROCEDURE: Haploidentical Hematopoietic Cell Transplantation

BIOLOGICAL: Lapine T-Lymphocyte Immune Globulin

PROCEDURE: Lumbar Puncture

PROCEDURE: Matched Unrelated Donor Hematopoietic Cell Transplantation

DRUG: Melphalan

DRUG: Methotrexate

PROCEDURE: Multigated Acquisition Scan

DRUG: Mycophenolate Mofetil

PROCEDURE: Myeloablative Conditioning

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

BIOLOGICAL: Rituximab

PROCEDURE: T-Cell Depletion Therapy

DRUG: Tacrolimus

DRUG: Thiotepa

RADIATION: Total-Body Irradiation

Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma
BTK inhibition and checkpoint blockade are promising classes of therapy for central nervous system (CNS) lymphoma and have demonstrated efficacy with acceptable toxicity. A multidrug approach may carry a higher chance of durable efficacy in this aggr...

DRUG: Durvalumab

DRUG: Acalabrutinib

Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Ye...
This is a multi-center, open-label phase II study to assess the efficacy of a novel fitness-adapted regimen in previously untreated older patients with classical Hodgkin lymphoma. All participants will receive up to a total of 8 cycles of pembrolizum...

DRUG: Pembrolizumab

DRUG: Doxorubicin

DRUG: Vinblastine

DRUG: Dacarbazine

DRUG: Brentuximab vedotin

Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
The purpose of this study is to see if Isatuximab can alter the immune system in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. The investigators will see if Isatuximab makes changes to the imm...

DRUG: Isatuximab

OTHER: Standard Procedures

Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
The main purpose of this study to find the ideal dose for the combination treatment of Zanubrutinib and Tafasitamab in patients with mantle cell lymphoma. Another purpose is to assess how well the combination treatment works in patients with the stud...

DRUG: Zanubrutinib

DRUG: Tafasitamab

Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
This is a Phase I/II, multicenter, open-label, dose escalation/dose-expansion study to evaluate the tolerability, safety, and the maximum tolerated dose (MTD) of ruxolitinib when given with fixed dose nivolumab in patients with relapsed or refractory...

DRUG: Ruxolitinib

DRUG: Nivolumab

Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides
This phase II trial studies how well ultra low dose radiation therapy works in treating patients with mycosis fungoides. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving ultra low doses of radiation may help con...

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

RADIATION: Radiation Therapy

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Agg...
The purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as monotherapy and in combination in participants with select B-cell lymphomas including mantle cell lymphoma (MCL), Richter's transformation lymphoma (RTL), f...

BIOLOGICAL: Zilovertamab vedotin

DRUG: Nemtabrutinib

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Chronic Lymphocytic Leukemia (C...
The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of the study drugs, zanubrutinib, obinutuzumab, and venetoclax, given in combination as a treatment for C...

DRUG: Zanubrutinib

DRUG: Obinutuzumab

DRUG: Venetoclax

CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
The subject has a type of lymph gland cancer called Lymphoma. The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibo...

GENETIC: CAR T Cells

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic ...
This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The purpose of this study is to evaluate the safety a...

BIOLOGICAL: UCART22

BIOLOGICAL: CLLS52

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell malignancies. LP-168 is a small molecule inhibito...

DRUG: LP-168

DRUG: LP-168

Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
This is a single arm open-label multicenter phase I/II investigation of combination lenalidomide/Tafasitamab in patients with relapsed central nervous system (CNS) lymphoma. This is the first study to examine a naked anti-CD19 monoclonal antibody in ...

DRUG: Tafasitamab

DRUG: Lenalidomide

Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
This will be a randomized, placebo-controlled trial with a 2x2 factorial design testing the effects of an NAD+ precursor (NR) and exercise on skeletal muscle quality and VO2max in AYA HCT survivors. The primary outcome is the change in muscle streng...

DIETARY_SUPPLEMENT: Nicotinamide Riboside

DIETARY_SUPPLEMENT: Placebo

OTHER: Exercise Intervention

Vaccination With Flt3L, Radiation, and Poly-ICLC
This is a combination of 4 therapies, three of which are used to treat a single "target site" of your cancer (such as a lymph node or a single tumor), and the 4th is given directly into the blood stream (intravenous or "IV"). 1. Radiation: The targe...

DRUG: Pembrolizumab

DRUG: Flt3L

RADIATION: Radiation

DRUG: Poly ICLC

Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cells (flat do...

DRUG: MT-601

Inotuzumab Ozogamicin in Treating Patients with B-cell Acute Lymphocytic Leukemia with Positive Mini...
This phase II trial studies how well inotuzumab ozogamicin works in treating patients with B-cell acute lymphocytic leukemia with positive minimal residual disease. Inotuzumab ozogamicin is a monoclonal antibody called inotuzumab linked to a toxic ag...

BIOLOGICAL: Inotuzumab Ozogamicin

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescent...
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hematopoietic cel...

DIAGNOSTIC_TEST: NGS-MRD

DRUG: Myeloablative allogeneic HCT with a non-TBI conditioning regimen

Allo HSCT Using RIC and PTCy for Hematological Diseases
This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem ce...

BIOLOGICAL: Peripheral Blood Stem Cell Transplant

DRUG: Allopurinol 300 MG

DRUG: Fludarabine

DRUG: Cyclophosphamide

BIOLOGICAL: Bone Marrow Cell Transplant

RADIATION: Total Body Irradiation

DRUG: Sirolimus Pill

DRUG: Mycophenolate Mofetil

Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma
This phase II trial tests how well lenalidomide and epcoritamab works in treating patients with follicular lymphoma that has not been previously treated. Although follicular lymphoma is incurable, prognosis has improved for both early and advanced st...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

OTHER: Electronic Health Record Review

BIOLOGICAL: Epcoritamab

DRUG: Lenalidomide

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Positron Emission Tomography

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (...
The purpose of this trial is to measure the safety and effectiveness of epcoritamab (EPKINLY™), either by itself or together with other therapies, when treating subjects with B-cell non-Hodgkin Lymphoma (B-NHL). The aim of the first part of the trial...

DRUG: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone

DRUG: rituximab and lenalidomide

DRUG: rituximab and bendamustine

DRUG: rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin

DRUG: gemcitabine and oxaliplatin

BIOLOGICAL: Epcoritamab

DRUG: rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone

DRUG: Lenalidomide

DRUG: rituximab, ifosfamide, carboplatin, and etoposide phosphate

BIOLOGICAL: Epcoritamab

BIOLOGICAL: Epcoritamab

BIOLOGICAL: Epcoritamab

BIOLOGICAL: Epcoritamab

BIOLOGICAL: Epcoritamab

BIOLOGICAL: Epcoritamab

BIOLOGICAL: Epcoritamab

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Background: Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. Most people with this cancer can be cured. But those who are not cured have a poor prognosis. Researchers want to add another drug to standard treatment see i...

DRUG: DA-EPOCH

BIOLOGICAL: Rituximab

DRUG: CHOP

DRUG: Acalabrutinib

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
The purpose of this study is to test any good and bad effects of the study drug called ruxolitinib. Ruxolitinib works by blocking a protein called JAK. JAK works along with another protein called STAT and is important for survival of many T or NK-cel...

DRUG: Ruxolitinib

Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or...
This early phase I clinical trial evaluates bridging radiation therapy given before chimeric antigen receptor (CAR) T-cell infusion to treat large B-cell lymphoma (LBCL) that has come back (relapsed) or has not responded to previous treatment (refrac...

PROCEDURE: Biospecimen Collection

BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy

PROCEDURE: Computed Tomography

RADIATION: External Beam Radiation Therapy

PROCEDURE: Leukapheresis

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Positron Emission Tomography

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymp...
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017 monotherap...

BIOLOGICAL: JCAR017 (lisocabtagene maraleucel)

BIOLOGICAL: JCAR017 (lisocabtagene maraleucel) + ibrutinib

BIOLOGICAL: JCAR017 (lisocabtagene maraleucel) + venetoclax

A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients with DLBCL
The purpose of this study is to test the effectiveness and safety of polatuzumab vedotin in combination with R-miniCHP in patients 75 years and older with DLBCL.

DRUG: Polatuzumab vedotin

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Prednisone

Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are proteins that protect the body...

BIOLOGICAL: ATLCAR.CD30 cells

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas T...
This phase I trial tests the safety, side effects, and best dose of combination therapy with tazemetostat and belinostat in treating patients with lymphomas that have returned (relapsed) or resisted treatment (refractory). Tazemetostat is in a class ...

DRUG: Belinostat

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

OTHER: Pharmacokinetic Study

PROCEDURE: Positron Emission Tomography and Computed Tomography Scan

DRUG: Tazemetostat

Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
Patients are in 2 cohorts: Cohort 1: dexamethasone, methotrexate, ifosfamide, pegaspargase, and etoposide (modified SMILE) chemotherapy regimen alone and pembrolizumab in children, adolescents, and young adults with advanced stage NK lymphoma and le...

DRUG: Methotrexate

DRUG: pralatraxate,

DRUG: Ifosfamide

DRUG: Dexamethasone

DRUG: Etoposide

DRUG: calaspargase pegol

DRUG: cyclophosphamide

DRUG: Doxorubicin

DRUG: Prednisone

DRUG: Brentuximab Vedotin

A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell N...
This study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL). The main purpose of this study is to assess the effectiveness of odronextamab in destroying cancer cells and to learn more abou...

DRUG: Odronextamab

Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
This is a multicenter, open-label, Phase 1 study that will be conducted in two parts. Part 1 is the dose escalation of APG-5918. Part 2 is the dose expansion of APG-5918. APG-5918 will be administered orally. Patients will be treated in 28-day cycle...

DRUG: APG-5918

WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
A first-in-human, Phase 1, open-label, multicenter study of WTX-330 administered as a monotherapy to patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma.

DRUG: WTX-330

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291...
Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-291 in...

DRUG: ABBV-291

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine a...
This phase I trial tests safety, side effects and best dose of B-cell activating factor receptor (BAFFR)-based chimeric antigen receptor T-cells, with fludarabine and cyclophosphamide lymphodepletion, for the treatment of patients with B-cell hematol...

BIOLOGICAL: Autologous BAFFR-targeting CAR T Cells

DRUG: Bendamustine

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration and Biopsy

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

PROCEDURE: Echocardiography

DRUG: Fludarabine

PROCEDURE: Leukapheresis

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Positron Emission Tomography

Cord Blood Transplant in Adults with Blood Cancers
Cord blood transplants (CBT) are a standard treatment for adults with blood cancers. MSK has developed a standard ("optimized") practice for cord blood transplant (CBT). This optimized practice includes how patients are evaluated for transplant, the ...

DRUG: Conditioning Chemotherapy

BIOLOGICAL: Cord blood graft

Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
This phase II trial investigates how well brentuximab vedotin and bendamustine work in treating patients with follicular lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Brentuximab vedotin is a monoclonal antibod...

DRUG: Bendamustine Hydrochloride

DRUG: Brentuximab Vedotin

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
The purpose of this study is to improve upon the TINI study treatment. The study will test the ability of a type of immunotherapy called blinatumomab to clear persistent leukemia. Blinatumomab targets CD19 which is located on the leukemia cells outer...

DRUG: Dexamethasone

DRUG: Mitoxantrone

DRUG: PEG asparaginase

DRUG: Bortezomib

DRUG: Vorinostat

DRUG: Mercaptopurine

DRUG: Methotrexate

DRUG: Blinatumomab

DRUG: Ziftomenib

A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory ...
To learn if the combination of axicabtagene ciloleucel (axi-cel) and glofitamab as first-line therapy in high-risk LBCL participants or as second-line therapy in LBCL participants can help to control the disease.

DRUG: Glofitamab

DRUG: Obinutuzumab

DRUG: Axi-cel

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-...
This phase Ib trial studies the effects of NKTR-255 in combination with chimeric antigen (CAR)-T cell therapy and to see how well they work in treating patients with large B-cell lymphoma that has come back (relapsed) or does not respond to treatment...

DRUG: Cyclophosphamide

DRUG: Fludarabine

BIOLOGICAL: Lisocabtagene Maraleucel

DRUG: Polymer-conjugated IL-15 Receptor Agonist NKTR-255

PROCEDURE: X-Ray Imaging

PROCEDURE: Echocardiography

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Lumbar Puncture

PROCEDURE: Computed Tomography

PROCEDURE: Positron Emission Tomography

PROCEDURE: Biospecimen Collection

PROCEDURE: Biopsy

Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T C...
This phase I trial evaluates the best dose, possible benefits and/or side effects of fludarabine and cyclophosphamide with or without rituximab before CD19 chimeric antigen receptor T cells in treating patients with diffuse large B-cell lymphoma that...

BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy

DRUG: Cyclophosphamide

DRUG: Fludarabine Phosphate

BIOLOGICAL: Rituximab

Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cell...
Patients eligible for this study have a type of blood cancer called T-cell leukemia or lymphoma (lymph gland cancer). The body has different ways of fighting infection and disease. This study combines two different ways of fighting disease with anti...

GENETIC: CD7.CAR/28zeta CAR T cells

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refrac...
This phase II trial tests the safety and best dose of revumenib in combination with chemotherapy, and evaluates whether this treatment improves the outcome in infants and young children who have leukemia that has come back (relapsed) or does not resp...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

DRUG: Calaspargase Pegol

DRUG: Cytarabine

PROCEDURE: Echocardiography

DRUG: Fludarabine Phosphate

DRUG: Hydrocortisone Sodium Succinate

PROCEDURE: Lumbar Puncture

DRUG: Methotrexate

PROCEDURE: Multigated Acquisition Scan

DRUG: Prednisolone

DRUG: Prednisone

DRUG: Revumenib

DRUG: Vincristine Sulfate

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults Wi...
This is a single arm, open-label, multi-center, Phase 1 study to determine the safety and tolerability of an experimental therapy called NKX019 (allogeneic CAR NK cells targeting CD19) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), ...

BIOLOGICAL: NKX019

A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Rela...
To find a recommended dose of valemetostat that can be given in combination with rituximab and lenalidomide to patients with follicular lymphoma. The safety and effects of this drug combination will also be studied

DRUG: Rituximab

DRUG: Lenalidomide

DRUG: Valemetostat

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearrang...
The purpose of this study is to provide continued treatment with alectinib or crizotinib as applicable to participants with ALK- or RET positive cancer who were previously enrolled in any Roche-sponsored alectinib study and who are deriving continued...

DRUG: Alectinib

DRUG: Crizotinib

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory So...
This phase I/II trial tests the safety, side effects, and best dose of entinostat and ZEN003694 in treating patients with solid tumors or lymphoma that has spread to other places in the body (advanced) or does not respond to treatment (refractory). E...

DRUG: BET Bromodomain Inhibitor ZEN-3694

PROCEDURE: Core Biopsy

DRUG: Entinostat

A Study of Mosunetuzumab in People With Follicular Lymphoma
The purpose of this study is to find out if mosunetuzumab is an effective treatment in people with follicular lymphoma that was recently diagnosed and have not yet received any treatments for their disease.

DRUG: Mosunetuzumab

DRUG: Zanubrutinib

Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults with Relapsed/Refractory AML,...
This is a Phase I, open-label, non-randomized, dose escalation study in adolescents and adults with relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, or mixed phenotype acute leukemia. Patients will receive continuous oral MRX...

DRUG: MRX-2843

Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insuffi...
This partially randomized clinical trial studies cholecalciferol in improving survival in patients with newly diagnosed cancer with vitamin D insufficiency. Vitamin D replacement may improve tumor response and survival and delay time to treatment in ...

DIETARY_SUPPLEMENT: Cholecalciferol

OTHER: Laboratory Biomarker Analysis

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.

DRUG: AVM0703

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refr...
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). I...

DRUG: Asparaginase Erwinia chrysanthemi

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration and Biopsy

DRUG: Calaspargase Pegol

DRUG: Cyclophosphamide

DRUG: Cytarabine

PROCEDURE: Diagnostic Imaging

BIOLOGICAL: Inotuzumab Ozogamicin

DRUG: Leucovorin Calcium

PROCEDURE: Lumbar Puncture

DRUG: Methotrexate

DRUG: Pegaspargase

DRUG: Vincristine

A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)
Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory to be changed (modified) to become 19-28z/IL-18, the CAR T-cell therapy t...

BIOLOGICAL: 19-28z/IL-18 CAR T cells

Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL
This is an international, multicenter, multi-arm, phase Ib, model-based dose-escalation study. The primary objectives of the study in each arm is to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), dose limiting toxicities...

DRUG: Pembrolizumab

DRUG: Pralatrexate

DRUG: Decitabine

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Ma...
B-cell malignancies are a group of cancers of B lymphocytes, a type of white blood cell responsible for fighting infections. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-525 as a monot...

DRUG: ABBV-525

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Co...
The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after a period of improvement after that follows a treat...

DRUG: Tazemetostat

DRUG: Tazemetostat

DRUG: Placebo oral tablet

COMBINATION_PRODUCT: Lenalidomide

COMBINATION_PRODUCT: Rituximab

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Ref...
Background: B-cell leukemias and lymphomas are cancers that are often difficult to treat. The primary objective of this study is to determine the ability to take a patient's own cells (T lymphocytes) and grow them in the laboratory with the CD19/CD2...

BIOLOGICAL: CD19/CD22 CAR T-Cells

DRUG: Fludarabine

DRUG: Cyclophosphamide

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of CD20-expressing B-cell malignancies. The ACE1831-001 study is an open-label, Phase I, first-in-hum...

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: ACE1831

DRUG: Obinutuzumab

Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
This research is being done to learn whether drug called itacitinib, which is a novel inflammation- and immune-lowering drug (immunosuppressant), can be given before and after non-myeloablative peripheral blood stem cell transplantation (PBSCT; also ...

DRUG: Itacitinib

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent ...
The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients with indolent NHL

BIOLOGICAL: EO2463

DRUG: lenalidomide

BIOLOGICAL: rituximab

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic N...
The purpose of this study is to evaluate sacituzumab tirumotecan versus chemotherapy (docetaxel or pemetrexed) for the treatment of previously-treated non-small cell lung cancer (NSCLC) with exon 19del or exon 21 L858R EGFR mutations (hereafter refer...

BIOLOGICAL: Sacituzumab tirumotecan

DRUG: Docetaxel

DRUG: Pemetrexed

Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromo...
To learn if the combination of blinatumomab and asciminib can help to control Ph+ ALL.

DRUG: Blinatumomab

DRUG: Asciminib

Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Ther...
This is an interventional study to evaluate the use of CTO1681 in preventing or reducing CAR T-cell-induced toxicities like cytokine release syndrome (CRS). This study will enroll adult patients with DLBCL who are scheduled to receive CD19-directed C...

DRUG: CTO1681 10 μg

DRUG: CTO1681 20 μg

DRUG: CTO1681 30 μg

Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Le...
This phase II trial studies how well ibrutinib and blinatumomab work in treating patients with B acute lymphoblastic leukemia that has come back or is not responding to treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the ...

BIOLOGICAL: Blinatumomab

DRUG: Ibrutinib

Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
This is a multicenter, open-label, Phase 1 study of orally administered VMD-928 in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative...

DRUG: VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)

SPARK-ALL: Calaspargase Pegol in Adults With ALL
The purpose of this phase 2/3 study is to confirm the recommended doses and to evaluate the safety and pharmacodynamics of Calaspargase pegol for the treatment of adult patients with Philadelphia-negative Acute Lymphoblastic Leukemia.

DRUG: Calaspargase pegol (S95015)

Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular L...
This randomized phase I/II trial studies radiation therapy and rituximab in treating patients with stage I-II grade 1 or grade 2 follicular lymphoma. Radiation therapy uses high energy x-rays to kill cancer cells. Immunotherapy with monoclonal antibo...

OTHER: Clinical Observation

RADIATION: Radiation Therapy

BIOLOGICAL: Rituximab

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refr...
This phase I trial tests the safety, side effects and best infusion dose of genetically engineered cells called anti-CD19/CD20/CD22 chimeric antigen receptor (CAR) T-cells following a short course of chemotherapy with cyclophosphamide and fludarabine...

BIOLOGICAL: Anti-CD19/CD20/CD22 CAR T-Cells

DRUG: Cyclophosphamide

DRUG: Fludarabine Phosphate

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared t...
The primary purpose of the study is to evaluate whether biweekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce the rate of major bacterial infections per participant per year in B-cell CLL, MM, and NHL...

DRUG: Xembify

DRUG: Placebo

Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT
This trial will assess the feasibility of alpha/beta T-cell and B-cell depleted allogeneic hematopoietic cell transplantation (HCT) followed by blinatumomab therapy for high-risk B cell acute lymphoblastic leukemia (ALL) as a means of reducing rates ...

DEVICE: Alpha/Beta T-cell and B-cell depleted HCT

DRUG: Blinatumomab

A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Ac...
The researchers are doing this study to see if early reinfusion of tisagenlecleucel can keep participants in B-CEll ApLasia at 6 months after their first infusion. The researchers will also look at the safety of early reinfusion and how effective it ...

BIOLOGICAL: Tisagenlecleucel

Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lympho...
This phase I trial tests the safety, side effects, and best dose of venetoclax in combination with a pediatric-inspired chemotherapy regimen known as C10403 in treating patients with newly diagnosed B cell acute lymphoblastic leukemia. Venetoclax may...

DRUG: Cyclophosphamide

DRUG: Cytarabine

DRUG: Daunorubicin Hydrochloride

DRUG: Mercaptopurine

DRUG: Methotrexate

DRUG: Pegaspargase

DRUG: Prednisone

DRUG: Venetoclax

DRUG: Vincristine Sulfate

Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lym...
The subject has a type of cancer or lymph gland disease associated with a virus called Epstein Barr Virus (EBV), which has come back, is at risk of coming back, or has not gone away after standard treatments. This research study uses special immune s...

BIOLOGICAL: MABEL CTLs

DRUG: Cyclophosphamide

DRUG: Fludarabine

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
This is an open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety of an autologous T-cell therapy (EB103) and to determine the Recommended Phase II Dose (RP2D) in adult subjects (≥ 18 years of age) who have relapsed...

BIOLOGICAL: EB103

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-102...
The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marg...

DRUG: Nemtabrutinib

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refra...
The goal of this clinical study is test how well the study drug, axicabtagene ciloleucel, works in participants with relapsed/refractory follicular lymphoma

BIOLOGICAL: Axicabtagene Ciloleucel

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Lenalidomide

DRUG: Rituximab

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Prednisone

DRUG: Bendamustine

Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma
This phase I/II trial studies the safety of acalabrutinib and axicabtagene ciloleucel in treating patients with B-cell lymphoma. Acalabrutinib may stop the growth of tumor cells by blocking key pathways needed for cell growth. Immunotherapy with axic...

DRUG: Acalabrutinib

BIOLOGICAL: Axicabtagene Ciloleucel

A Study of CA-4948 in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma
This is a multi-center, open-label trial to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib (CA-4948) in adult patients with relapsed or refractory (R/R) hematologic malignancies. This trial ...

DRUG: Emavusertib

DRUG: ibrutinib

Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma
The goal of this clinical research study is to learn if radiation therapy and chemotherapy can help control Stage 1 and/or 2 NK cell lymphoma. The safety of the radiation and chemotherapy combination will also be studied. This is an investigational ...

RADIATION: Radiation Therapy

DRUG: Dexamethasone

DRUG: Etoposide phosphate

DRUG: Ifosfamide

DRUG: Mesna

DRUG: Carboplatin

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclopho...
This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone marrow stem cell trans...

DRUG: Busulfan

DRUG: Busulfan

DRUG: Fludarabine

RADIATION: Total-body irradiation

DRUG: Cyclophosphamide

DRUG: Melphalan

PROCEDURE: PBSC Hematopoietic Stem Cell Transplantation (HSCT)

PROCEDURE: Bone Marrow Hematopoietic Stem Cell Transplantation

DRUG: Post-transplant Cyclophosphamide

DRUG: Mesna

DRUG: Tacrolimus

DRUG: Mycophenolate Mofetil

OTHER: Patient-Reported Outcomes

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
The purpose of this study is to find out whether the combination of glofitamab and lenalidomide is an effective treatment for relapsed or refractory Mantle Cell Lymphoma

DRUG: Glofitamab

DRUG: Obinutuzumab

DRUG: Lenalidomide

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE As Salvage Therapy for Transplant Eligi...
This phase II clinical trial evaluates tafasitamab and lenalidomide followed by tafasitamab and the carboplatin, etoposide and ifosfamide (ICE) regimen as salvage therapy for transplant eligible patients with large B-cell lymphoma that has come back ...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

DRUG: Carboplatin

PROCEDURE: Computed Tomography

DRUG: Etoposide

DRUG: Ifosfamide

DRUG: Lenalidomide

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Tafasitamab

Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell T...
This phase I/II trial studies how well cytokine-treated veto cells work in treating patients with hematologic malignancies following stem cell transplant. Giving chemotherapy and total-body irradiation before a stem cell transplant helps stop the gro...

BIOLOGICAL: Anti-Thymocyte Globulin

DRUG: Cyclophosphamide

BIOLOGICAL: Cytokine-treated Veto Cells

DRUG: Fludarabine

PROCEDURE: Peripheral Blood Stem Cell Transplantation

RADIATION: Total-Body Irradiation

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Comb...
This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab or glofitamab in combination with CELMoDs (CC-220 or CC-99282) in participants with B-cell NHL.

DRUG: SC Mosunetuzumab

DRUG: IV Glofitamab

DRUG: CC-220

DRUG: CC-99282

DRUG: Obinutuzumab

DRUG: Tocilizumab

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mix...
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phe...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Bone Scan

DRUG: Calaspargase Pegol

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

DRUG: Cytarabine

DRUG: Daunorubicin Hydrochloride

DRUG: Dexamethasone

DRUG: Doxorubicin Hydrochloride

BIOLOGICAL: Inotuzumab Ozogamicin

DRUG: Leucovorin Calcium

PROCEDURE: Magnetic Resonance Imaging

DRUG: Mercaptopurine

DRUG: Methotrexate

DRUG: Pegaspargase

PROCEDURE: Positron Emission Tomography

DRUG: Prednisolone

OTHER: Questionnaire Administration

RADIATION: Radiation Therapy

RADIATION: Radiation Therapy

DRUG: Thioguanine

DRUG: Vincristine Sulfate

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recu...
Background: Acute lymphoblastic leukemia (ALL) is the most common cancer in children. About 90% of children and young adults who are treated for ALL can now be cured. But if the disease comes back, the survival rate drops to less than 50%. Better tr...

BIOLOGICAL: CD19/CD22-CAR-transduced T cells

DRUG: cyclophosphamide

DRUG: fludarabine

Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma
This phase II trial compares the safety, side effects and effectiveness of reduced dose radiation therapy to standard of care dose radiation in treating patients with indolent non-Hodgkin lymphoma. Radiation therapy uses high energy x-rays, particles...

PROCEDURE: Computed Tomography

PROCEDURE: Endoscopic Procedure

RADIATION: Involved-site Radiation Therapy (3 Fractions)

RADIATION: Involved-site Radiation Therapy (12 Fractions)

PROCEDURE: Positron Emission Tomography

OTHER: Questionnaire Administration

A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies o...
This is a Phase 1, open-label, dose escalation study to determine the safety and preliminary efficacy of voruciclib monotherapy in subjects with relapsed/refractory B cell malignancies or AML after failure of standard therapies or voruciclib in combi...

DRUG: voruciclib monotherapy

DRUG: voruciclib and venetoclax

First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With R...
This is an open-label, multicenter, Phase 1/Phase 2, dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics and anti-leukemic activity of SAR443579 in various hematological malignancies.

DRUG: SAR443579

Epcoritamab and Rituximab for First-line Follicular Lymphoma
The purpose of this study is to determine how effective and safe the combination of rituximab and epcoritamab is in treating patients with Follicular Lymphoma (FL) and who have not received other treatments for their lymphoma. The names of the study...

DRUG: Epcoritamab

DRUG: Rituximab

Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
Assess the safety and tolerability, identify dose-limiting toxicities (DLT) and determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D) of APG-2575.

DRUG: APG2575

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblas...
This trial aims to demonstrate the feasibility of this approach to reliably generate product and to safely administer the product to patients who have B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia.

DRUG: Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)

A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies
ELiPSE-1 is a Phase 1, multi-center, dose-finding study to evaluate the safety, pharmacokinetics, and preliminary efficacy of CNTY-101 in participants with relapsed or refractory cluster of differentiation (CD)19-positive B-cell malignancies.

BIOLOGICAL: CNTY-101

BIOLOGICAL: IL-2

DRUG: Lymphodepleting Chemotherapy

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hemat...
This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without daratumumab or rituximab to eva...

DRUG: IDP-023

DRUG: Rituximab

DRUG: Daratumumab

DRUG: Interleukin-2

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Mesna

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large ...
This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleucel, axicabta...

BIOLOGICAL: Axicabtagene Ciloleucel

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

DRUG: Fludarabine

BIOLOGICAL: Lisocabtagene Maraleucel

BIOLOGICAL: Mosunetuzumab

OTHER: Patient Observation

DRUG: Polatuzumab Vedotin

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Tisagenlecleucel

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
The purpose of this study is to determine if giving an experimental drug called venetoclax in combination with lenalidomide and rituximab is safe and effective for treating people with Mantle Cell Lymphoma (MCL).

DRUG: Venetoclax

DRUG: Lenalidomide

DRUG: Rituximab

A Study of REC-1245 in Participants with Unresectable, Locally Advanced, or Metastatic Cancer
This is a multi-center, open-label study to investigate the safety, tolerability, PK, PD, and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid ...

DRUG: REC-1245

Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
This phase II trial tests the safety, side effects and effectiveness of mosunetuzumab in treating patients with slow growing (indolent) B-cell lymphoma. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

PROCEDURE: Magnetic Resonance Imaging

BIOLOGICAL: Mosunetuzumab

PROCEDURE: Positron Emission Tomography

OTHER: Questionnaire Administration

Co-administration of CART22-65s and huCART19 for B-ALL
This study will evaluate the safety and efficacy of administering two CAR T cell products, huCART19 and CART22-65s, in children with advanced B cell Acute Lymphoblastic Leukemia (B-ALL).

BIOLOGICAL: Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)

BIOLOGICAL: Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)

Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma
Background: Primary effusion lymphoma (PEL) is an aggressive form of cancer that affects cells in the immune system and lymph nodes. How PEL develops is not well understood, and this disease does not respond well to standard treatments for other typ...

DRUG: Daratumumab SC

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With ...
This phase II/III trial compares the side effects and activity of oral azacitidine in combination with the standard drug therapy (reduced dose rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone \[R-miniCHOP\]) versus R-miniCHOP alon...

PROCEDURE: Biospecimen Collection

DRUG: Cyclophosphamide

DRUG: Doxorubicin Hydrochloride

DRUG: Oral Azacitidine

DRUG: Prednisone

OTHER: Questionnaire Administration

BIOLOGICAL: Rituximab

DRUG: Vincristine Sulfate

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patient...
The purpose of the study is to evaluate glofitamab + gemcitabine + oxaliplatin in participants in the United States, including under-represented racial and ethnic populations, that have relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBC...

DRUG: Glofitamab

DRUG: Tocilizumab

DRUG: Obinutuzumab

DRUG: Gemcitabine

DRUG: Oxaliplatin

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Reduced Dose Post Tra...
The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question\[s\] it a...

DRUG: Busulfan

DRUG: Fludarabine

PROCEDURE: PBSC Hematopoietic Stem Cell Transplantation (HSCT)

DRUG: Post-Transplant Cyclophosphamide

DRUG: Mesna

DRUG: Tacrolimus

DRUG: Mycophenolate Mofetil

OTHER: Patient Reported Outcomes

DRUG: Melphalan

RADIATION: Total-body irradiation

DRUG: Cyclophosphamide

Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia
This trial is a limited multi-center, Phase II study to evaluate inotuzumab ozogamicin (Besponsa) in pediatric patients with MRD positive CD22-positive B-lymphoblastic leukemia (B-ALL). Some patients with newly diagnosed ALL maintain low levels of M...

DRUG: Inotuzumab ozogamicin

DRUG: Methotrexate

DRUG: Hydrocortisone

DRUG: Cytarabine

DRUG: Diphenhydramine

DRUG: Acetaminophen

DRUG: Methylprednisolone

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte At...
The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The ...

DRUG: TAB004

DRUG: Toripalimab

Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
This is an open label, single center, non-randomized dose de-escalation phase I study of combination of BV and Mogamulizumab. The primary objective of the study is to assess the safety and tolerability of the combination. The primary objective is al...

DRUG: Mogamulizumab

DRUG: Brentuximab vedotin

Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients With r/r NHL and...
This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL and r/r B-cell NHL.

BIOLOGICAL: Azer-cel

DRUG: Fludarabine

DRUG: Cyclophosphamide

DRUG: IL-2

DRUG: Bendamustine

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabru...
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior therapy. Th...

DRUG: Nemtabrutinib

DRUG: Ibrutinib

DRUG: Acalabrutinib

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin L...
This phase I/II trial finds out the best dose, possible benefits and/or side effects of ALX148 in combination with rituximab and lenalidomide in treating patients with indolent and aggressive B-cell non-Hodgkin lymphoma. Immunotherapy with ALX148, ma...

DRUG: CD47 Antagonist ALX148

DRUG: Lenalidomide

BIOLOGICAL: Rituximab

Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma
The purpose of this study is to determine the correct dose and safety of combining two new cancer drugs, loncastuximab tesirine and venetoclax, as a treatment for relapsed or refractory B cell lymphoma.These drugs are used to treat some lymphomas, bu...

DRUG: Loncastuximab tesirine

DRUG: Venetoclax

SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
This phase 2 trial studies the immune response to GEO-CM04S1 (previously designated as COH04S1) compared to standard of care (SOC) mRNA SARS-COV-2 vaccine in patients with blood cancer who have received stem cell transplant or cellular therapy. GEO-...

BIOLOGICAL: COVID-19 Vaccine

OTHER: Diagnostic Laboratory Biomarker Analysis

BIOLOGICAL: Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1

A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab...
The purpose of this study is to learn about the effects of two study medicines (maplirpacept \[PF-07901801\] and glofitamab) when given together for the treatment of diffuse large B-cell lymphoma (DLBCL) that is relapsed or is refractory. Relapsed me...

DRUG: maplirpacept (PF-07901801)

DRUG: Glofitamab

DRUG: Obinutuzumab

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
This clinical trial is evaluating a drug called AC676 in participants with Relapsed/Refractory B-cell Malignancies. The main goals of the study are to: * Identify the recommended dose of AC676 that can be given safely to participants * Evaluate the ...

DRUG: AC676

FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)
This is a phase 1 study of FT522 administered with rituximab in participants with relapsed/refractory B-cell lymphoma (R/R BCL). The primary objectives of the study are to evaluate the safety and tolerability of FT522 in combination with rituximab, a...

DRUG: FT522

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Bendamustine

Studying TAK-243 in Patients With Advanced Cancer
This phase I trial studies the side effects and best dose of ubiquitin-activating enzyme (UAE) inhibitor TAK-243 (TAK-243) in treating patients with a solid tumor that may have spread from where it first started to nearby tissue, lymph nodes, or dist...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

PROCEDURE: Echocardiography

PROCEDURE: Magnetic Resonance Imaging

DRUG: UAE Inhibitor TAK-243

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 M...
Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 3 indication-specific expansion cohorts to det...

DRUG: revumenib

DRUG: cobicistat

Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia
This phase II trial tests whether ruxolitinib works to shrink tumors in patients with T-cell large granular lymphocyte leukemia. Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

DRUG: Ruxolitinib

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.

DRUG: NX-2127

Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lympho...
This phase Ib/II trial is aimed at studying the combination of a drug named Selinexor (selective inhibitor of nuclear export) in combination with standard therapy for B cell Non-Hodgkin's lymphoma called R-CHOP. The investigators will establish maxim...

DRUG: Selinexor

Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma
This phase I trial tests the safety, side effects, and best dose of tegavivint in treating patients with large b-cell lymphomas that has come back (relapsed) or does not respond to treatment (refractory). Tegavivint may stop the growth of cancer cell...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

PROCEDURE: Positron Emission Tomography

DRUG: Tegavivint

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatmen...
This phase II trial studies how well a donor stem cell transplant, treosulfan, fludarabine, and total-body irradiation work in treating patients with blood cancers (hematological malignancies). Giving chemotherapy and total-body irradiation before a ...

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

DRUG: Cyclophosphamide

DRUG: Cyclosporine

BIOLOGICAL: Filgrastim

DRUG: Fludarabine

DRUG: Mycophenolate Mofetil

DRUG: Mycophenolate Sodium

RADIATION: Total-Body Irradiation

DRUG: Treosulfan

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Echocardiography

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

PROCEDURE: Positron Emission Tomography

Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refracto...
This phase Ib trial tests the safety, side effects, and effectiveness of humanized (hu)CD19-chimeric antigen receptor (CAR) T cell therapy in treating patients with CD19 positive B-cell acute lymphoblastic leukemia (ALL) that has come back after a pe...

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

BIOLOGICAL: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes

BIOLOGICAL: Cetuximab

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

PROCEDURE: Echocardiography

DRUG: Fludarabine

PROCEDURE: Leukapheresis

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Positron Emission Tomography

Gene Therapy for B-Cell Acute Lymphoblastic Leukemia
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19+ B-cell acute lymphoblastic leukemia (ALL).

GENETIC: Dose Level 1, VNX-101

GENETIC: Dose Level 2, VNX-101

GENETIC: Dose Level 3, VNX-101

GENETIC: Dose Level 4, VNX-101

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a possible treatment ...

DRUG: ARV-393

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV...
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. Chronic lymphocytic leukemia (CLL) is the most co...

DRUG: ABBV-319

Blinatumomab Bridging Therapy
The investigator is testing the ability of a biologically active therapy in blinatumomab, an anti-CD19/CD3 bispecific T-cell engager, to further reduce residual leukemia immediately prior to HCT to improve post-HCT outcomes.

DRUG: Blinatumomab

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
This phase I trial tests the safety, side effects, and best dose of nivolumab in combination with ASTX727 in treating B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodie...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

DRUG: Decitabine and Cedazuridine

BIOLOGICAL: Nivolumab

PROCEDURE: Positron Emission Tomography

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutan...
This phase I trial is to find out the best dose, possible benefits and/or side effects of third-party natural killer cells in combination with mogamulizumab in treating patients with cutaneous T-cell lymphoma or adult T-cell leukemia/lymphoma that ha...

DRUG: Cyclophosphamide

DRUG: Fludarabine

BIOLOGICAL: Mogamulizumab

BIOLOGICAL: Natural Killer Cell Therapy

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant
Cancer and treatment-related cognitive changes hinder resumption of normal routine and roles and worsen quality of life. Older adults undergoing hematopoietic cell transplantation (HCT) are at high-risk for cognitive impairment. Physical activity imp...

BEHAVIORAL: CHAMPS-II adapted to adults 60+ years in HCT setting

Venetoclax Basket Trial for High Risk Hematologic Malignancies
This trial is evaluating the safety and tolerability of venetoclax with chemotherapy in pediatric and young adult patients with hematologic malignancies, including myelodysplastic syndrome (MDS), acute myeloid leukemia derived from myelodysplastic sy...

DRUG: Venetoclax

DRUG: Azacitidine

DRUG: Cytarabine

DRUG: Methotrexate

DRUG: Hydrocortisone

DRUG: Leucovorin

DRUG: Dexamethasone

DRUG: Vincristine

DRUG: Doxorubicin

DRUG: Dexrazoxane

DRUG: Calaspargase Pegol

DRUG: Erwinia asparaginase

First in Human, Dose Escalation Study of AN4005
Open-label, multicenter, phase 1 study to investigate the safety, tolerability, and PK of AN4005 in patients with advanced tumors. This study is a first-in-human, dose escalation study with the objective to establish the MTD and/or RP2D of AN4005. E...

DRUG: AN4005-dose level 0

DRUG: AN4005-dose level 1

DRUG: AN4005-dose level 2

DRUG: AN4005-dose level 3

DRUG: AN4005-dose level 4

DRUG: AN4005-food effect

A Study of N-Acetylcysteine (N-AC) in People Receiving CAR T-cell Therapy for Lymphoma
The purpose of this study is to test the safety of N-AC when given in combination with Yescarta to people with lymphoma. This study will test different doses of N-AC to find the highest dose that causes few or mild side effects in participants.

DRUG: N-Acetylcysteine

EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma
This study is for patients that have a type of lymph gland disease called Hodgkin or non-Hodgkin Lymphoma or T/NK-lymphoproliferative disease which has come back or has not gone away after treatment, including the best treatment the investigators kno...

BIOLOGICAL: Dose Level 1A: 2 x 10^7 cells/m2

BIOLOGICAL: Dose Level 2A: 6 x 10^7 cells/m2

BIOLOGICAL: Dose Level 2B: 6 x 10^7 cells/m2

BIOLOGICAL: Dose Level 3B: 2 x 10^8 cells/m2

BIOLOGICAL: Dose Level 3A: 2 x 10^8 cells/m2

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory...
This is a single-arm, open label, multicenter Phase 1/2 study evaluating ALLO-501A in adult subjects with R/R LBCL and CLL/SLL. The purpose of the ALPHA2 study is to assess the safety, efficacy, and cell kinetics of ALLO-501A in adults with relapsed ...

GENETIC: ALLO-501A

BIOLOGICAL: ALLO-647

DRUG: Fludarabine

DRUG: Cyclophosphamide

Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic...
This phase Ib trial evaluates the side effects and best dose of choline salicylate given together with a low dose of selinexor in treating patients with non-Hodgkin or Hodgkin lymphoma, or multiple myeloma whose prior treatment did not help their can...

DRUG: Choline Salicylate

DRUG: Selinexor

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Ref...
The purpose of this study is to evaluate the safety and preliminary efficacy of ATA3219 in participants with relapsed/refractory (R/R) B-cell non-Hodgkin Lymphoma (NHL).

DRUG: ATA3219

Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignan...
This phase I trial studies the safety of transplantation with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells in conjunction with the immunomodulating drug, Zoledronate, given in the post-transplant pe...

PROCEDURE: TCRαβ+/CD19+ depleted Haploidentical HSCT

DRUG: Zoledronate

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
This is a single arm, open label, multicenter study phase 2 study of pembrolizumab and brentuximab in subjects with relapsed/refractory CD30 positive T-cell lymphoma (including peripheral T-cell lymphoma and cutaneous T-cell lymphoma) who have receiv...

DRUG: Brentuximab vedotin

DRUG: Pembrolizumab

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chron...
This phase II trial studies the effect of ascorbic acid and combination chemotherapy in treating patients with lymphoma that has come back (recurrent) or does not respond to therapy (refractory), clonal cytopenia of undetermined significance and chro...

DIETARY_SUPPLEMENT: Ascorbic Acid

DRUG: Carboplatin

DRUG: Cisplatin

DRUG: Cytarabine

DRUG: Dexamethasone

DRUG: Etoposide

DRUG: Gemcitabine Hydrochloride

DRUG: Ifosfamide

OTHER: Laboratory Biomarker Analysis

DRUG: Oxaliplatin

OTHER: Placebo Administration

OTHER: Questionnaire Administration

BIOLOGICAL: Rituximab

DRUG: Decitabine

PROCEDURE: Biospecimen Collection

PROCEDURE: Core Biopsy

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Echocardiography

PROCEDURE: Positron Emission Tomography

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Central Venous Cannula Insertion

PROCEDURE: Portacath Placement

PROCEDURE: Computed Tomography

Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV
Background: Less toxic and more effective treatments are needed for cancers caused by viruses. These cancers include Hodgkin and non-Hodgkin lymphoma, hepatocellular carcinoma, head and neck cancer, nasopharyngeal carcinoma, gastric cancer, anal can...

DRUG: Pomalidomide

DRUG: Nivolumab

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malign...
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell l...

BIOLOGICAL: Zilovertamab vedotin

Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refract...
The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of LP-284 and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) in patients with relapsed or refractory (R/R) lymphomas...

DRUG: LP-284

Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma
This study will have two Phases: Phase 1a and Phase 1b. The goal of Phase 1a of this clinical study is to learn more about the safety, tolerability and dosing of study drug KITE-197, in participants with relapsed or refractory large B-cell lymphoma (...

DRUG: KITE-197

DRUG: Cyclophosphamide

DRUG: Fludarabine

ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells
Despite the progress in the therapy, Hodgkin's Lymphoma (HL) remains fatal for more than 15% of patients. Even in patients who are cured, the morbidity of therapy is substantial and long-lasting. New therapeutic agents are required therefore not only...

DRUG: Chemotherapy

BIOLOGICAL: Cell infusion

A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Thera...
To learn if giving acalabrutinib, rituximab, and brexucabtagene autoleucel to patients with previously untreated high-risk mantle cell lymphoma (MCL) can help to control the disease.

DRUG: Acalabrutinib

DRUG: Rituximab

OTHER: Brexucabtagene Autoleucel

DRUG: Cyclophosphamide

DRUG: Fludarabine Phosphate

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed o...
This phase Ib trial studies the effects of venetoclax in combination with dasatinib, prednisone, rituximab and blinatumomab in treating patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) that is newly diagnosed or that ...

DRUG: Dasatinib

DRUG: Methotrexate

DRUG: Prednisone

BIOLOGICAL: Rituximab

DRUG: Venetoclax

BIOLOGICAL: Blinatumomab

PROCEDURE: Bone Marrow Aspiration and Biopsy

PROCEDURE: Lumbar Puncture

PROCEDURE: Biospecimen Collection

Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
This phase 1 pilot study examines the feasibility and safety of mosunetuzumab after autologous stem cell transplant for patients with aggressive B cell lymphomas. Mosunetuzumab is an antibody that has been engineered to attach to two target cells in ...

DRUG: Mosunetuzumab

A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphobla...
This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with relapsed/refractory T-ALL or T-LL. This study consists of Phase 1 dose-exploration cohorts, Phase 1 dose-expansion cohort(s), a Phase ...

BIOLOGICAL: BEAM-201

Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematol...
The purpose of the study is to find out if an investigational drug called PRGN-3007 UltraCAR-T cells (PRGN-3007 T cells) can help people with ROR1-positive hematologic chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), acute lymphoblasti...

DRUG: Fludarabine

DRUG: Cyclophosphamide

BIOLOGICAL: PRGN-3007

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymp...
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

BIOLOGICAL: Obinutuzumab

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

DRUG: Venetoclax

Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants Wi...
The purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemotherapy.

DRUG: Loncastuximab Tesirine

DRUG: Rituximab

DRUG: Gemcitabine

DRUG: Oxaliplatin

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
This research study combines 2 different ways of fighting disease: antibodies and T cells. Both antibodies and T cells have been used to treat patients with cancers, and both have shown promise, but neither alone has been sufficient to cure most pati...

BIOLOGICAL: iC9-CAR19 T cells

DRUG: Bendamustine

DRUG: Fludarabine

DRUG: AP1903

DRUG: Cyclophosphamide

CONFIRM: Magnetic Resonance Guided Radiation Therapy
This research is being done to determine the safety and feasibility of using a type of radiation guided by magnetic resonance imaging (MRI) and chemotherapy to treat patients with gastric and breast cancer. The name of the radiation machine involved ...

RADIATION: Viewray MRIdian® Linac

A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood St...
The UCB transplant is a type of stem cell transplant used to treat cancer of the blood or lymph glands. The UCB transplant has advantages over other types of transplants such as ease of obtaining the umbilical cord blood, absence of donor risks, redu...

DRUG: Hyperbaric oxygen

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib...
This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutinib may stop the growth of c...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Ibrutinib

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Rituximab

DRUG: Venetoclax

Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion
Patients with medical conditions requiring allogeneic hematopoietic cell transplantation (allo-HCT) are at risk of developing a condition called graft versus host disease (GvHD) which carries a high morbidity and mortality. This is a phase I/II study...

DEVICE: CliniMACS

A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well ...
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma. Follicular lymphoma is a type of non-Hodgkin lymphoma or NHL. Participa...

DRUG: Odronextamab

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Prednisone/Prenisolone

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.

DRUG: CTX-8371

Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukem...
This study will test if adding ruxolitinib to standard multi-drug chemotherapy regimen will be safe and tolerated in adolescents and young adults with newly diagnosed Ph-like acute lymphoblastic leukemia (ALL).

DRUG: Ruxolitinib

DRUG: Cyclophosphamide

DRUG: Cytarabine

DRUG: Mercaptopurine

DRUG: Vincristine

DRUG: Pegaspargase

DRUG: Rituximab

DRUG: Methotrexate (Intrathecal Administration)

DRUG: Methotrexate (Intravenous Administration)

DRUG: Dexamethasone

DRUG: Doxorubicin

DRUG: Thioguanine

DRUG: Methotrexate Oral Product

Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleu...
To find out if adding treatment with fecal microbiota transplantation (FMT) is effective at treating gut-related side effects of antibiotic treatment in participants who are receiving standard therapy with anti-CD19 chimeric antigen receptor T-cell (...

DRUG: Fecal Microbiota Transplantation

PROCEDURE: Chemotherapy

PROCEDURE: CAR-T Therapy

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Particip...
The purpose of this study is to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma (FL).

DRUG: Golcadomide

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Prednisone

DRUG: Bendamustine

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the ...
This phase II trial studies the effect of rituximab, lenalidomide, acalabrutinib, tafasitamab alone and in combination with chemotherapy in treating patients with newly diagnosed non-germinal center diffuse large B-cell lymphoma. Rituximab and tafasi...

DRUG: Acalabrutinib

DRUG: Cyclophosphamide

DRUG: Doxorubicin Hydrochloride

DRUG: Lenalidomide

DRUG: Prednisone

BIOLOGICAL: Rituximab

BIOLOGICAL: Tafasitamab

DRUG: Vincristine

Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for th...
This phase II trials studies the effects of yttrium-90 labeled anti-CD25 monoclonal antibody combined with BEAM chemotherapy conditioning in treating patients with Hodgkin lymphoma that does not response to treatment (refractory) or has come back (re...

BIOLOGICAL: Basiliximab

DRUG: Carmustine

DRUG: Cytarabine

DRUG: Etoposide

BIOLOGICAL: Genetically Engineered Hematopoietic Stem Progenitor Cells

BIOLOGICAL: Recombinant Granulocyte Colony-Stimulating Factor

BIOLOGICAL: Yttrium Y 90 Basiliximab

Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden ...
To learn if obinutuzumab in combination with CC-99282 can help to control previously untreated, high tumor burden FL

DRUG: Obinutuzumab

DRUG: CC-99282

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (h...
This study will determine the safety and efficacy of moving to a second-generation manufacturing process using the CliniMACS Prodigy platform to manufacture huCART19 cells for patients with B cell Acute Lymphoblastic Leukemia (B-ALL).

BIOLOGICAL: Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)

Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia
To assess the feasibility of oral dasatinib pulses (3 consecutive days per week) during the first month following infusion of brexucabtagene autoleucel (Tecartus) in adults with relapsed or refractory B-cell acute lymphoblastic leukemia.

DRUG: Dasatinib

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies

DRUG: VIP943 (QW)

DRUG: VIP943 (BIW)

Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma
This phase II trial tests how well giving pembrolizumab followed by chemotherapy with doxorubicin, vinblastine and dacarbazine works to treat patients with classical Hodgkin lymphoma. Pembrolizumab is a type of drug called a "monoclonal antibody (mAb...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

DRUG: Dacarbazine

DRUG: Doxorubicin

PROCEDURE: Echocardiography

PROCEDURE: Multigated Acquisition Scan

BIOLOGICAL: Pembrolizumab

PROCEDURE: Positron Emission Tomography

DRUG: Vinblastine

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to ...
This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that returned or ...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

DRUG: Lenalidomide

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Positron Emission Tomography

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

BIOLOGICAL: Tafasitamab

DRUG: Tazemetostat

DRUG: Zanubrutinib

Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
The purpose of this research study is to see if loncastuximab tesirine has any benefits at dose levels researchers found acceptable in earlier studies in patients with related forms of immune cell cancers. The researchers want to find out the effects...

DRUG: Loncastuximab tesirine 150 µg/Kg

DRUG: Loncastuximab tesirine 75µg/Kg

Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior ...
The primary objective of this study is to evaluate the safety of zanubrutinib (also known as BGB-3111) in chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström macroglobulinemia, mantle cell lymphoma, or marginal zone lymphoma patients...

DRUG: Zanubrutinib

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Othe...
This phase II trial studies the effect of acalabrutinib and obinutuzumab in treating patients with follicular lymphoma or other indolent non-Hodgkin lymphoma for which the patient has not received treatment in the past (previously untreated). Acalabr...

DRUG: Acalabrutinib

BIOLOGICAL: Obinutuzumab

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

Acalabrutinib and Venetoclax with or Without Early Obinutuzumab for the Treatment of High Risk, Recu...
This phase II trial studies how well acalabrutinib and venetoclax with or without early obinutuzumab work for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma that is high risk, has come back (recurrent), or does not respon...

DRUG: Acalabrutinib

BIOLOGICAL: Obinutuzumab

DRUG: Venetoclax

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymph...
This phase II Pediatric MATCH treatment trial studies how well ensartinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with ALK or ROS1 genomic alterations that have come back (recurrent) or does not re...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration and Biopsy

PROCEDURE: Bone Scan

PROCEDURE: Computed Tomography

DRUG: Ensartinib

OTHER: Laboratory Biomarker Analysis

PROCEDURE: Magnetic Resonance Imaging

OTHER: Pharmacological Study

PROCEDURE: Positron Emission Tomography

PROCEDURE: Radionuclide Imaging

PROCEDURE: X-Ray Imaging

ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia
This phase I/II trial studies the side effects and best dose of ADCT-602 in treating patients with B-cell lymphoblastic leukemia that has come back or does not respond to treatment. Monoclonal antibodies, such as ADCT-602, may interfere with the abil...

BIOLOGICAL: ADCT-602

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed ...
This phase II clinical trial tests a chemotherapy regimen (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin with or without rituximab \[DA-EPOCH+/-R\]) with the addition of targeted therapy (tafasitamab) for the trea...

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Etoposide

DRUG: Prednisone

BIOLOGICAL: Rituximab

BIOLOGICAL: Tafasitamab

DRUG: Vincristine

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

PROCEDURE: Lumbar Puncture

PROCEDURE: Biospecimen Collection

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
This is a non-randomized clinical trial to evaluate the safety and efficacy of CD22CART administered after lymphodepleting chemotherapy in adults with relapsed / refractory B Cell Lymphomas. All evaluable participants will be followed for overall sur...

DRUG: CD22CART Infusion

Study to Evaluate the Efficacy and Safety of Sonrotoclax in Participants With Waldenström's Macroglo...
This study will evaluate the safety and efficacy of the BCL2 inhibitor BGB-11417 (sonrotoclax) in participants with relapsed/refractory Waldenström's Macroglobulinemia (R/R WM) and in combination with zanubrutinib in adult participants with previousl...

DRUG: BGB-11417

DRUG: Zanubrutinib

Auto Stem Cell Transplant for Lymphoma Patients
This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.

DRUG: Etoposide

DRUG: BCNU

DRUG: AraC

DRUG: Melphalan

PROCEDURE: Peripheral blood stem cell transplantation

BIOLOGICAL: G-CSF

DRUG: Cyclophosphamide

RADIATION: Total Body Irradiation

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Maligna...
This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.

BIOLOGICAL: CTX112

Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
The main purpose of this study is to examine the outcome of a combined bone marrow and kidney transplant from a partially matched related (haploidentical or "haplo") donor. This is a pilot study, you are being asked to participate because you have a ...

PROCEDURE: Haploidentical Bone Marrow/Kidney

Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T...
A Phase I trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, adolescents, and yo...

DRUG: Daratumumab

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignanc...
Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine ...

DRUG: Tagraxofusp

DRUG: Fludarabine

DRUG: Cytarabine

DRUG: Dexamethasone

DRUG: Vincristine

DRUG: Azacitidine

DRUG: Methotrexate

DRUG: Cytarabine IT

DRUG: Hydrocortisone

Orphan Indications for CD19 Redirected Autologous T Cells
This is an open-label, four-cohort, phase 2 study to determine the efficacy of CART19 in pediatric and young adult patientswith hypodiploid (Cohort A) or t(17;19) B-ALL (Cohort B), infants with very high risk KMT2A B-ALL (Cohort C), and in patients w...

BIOLOGICAL: Murine CART19

IKS03 in Patients with Advanced B Cell Non-Hodgkin Lymphomas
This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in...

DRUG: IKS03

A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Youn...
The purpose of this study is to evaluate the safety and efficacy of glofitamab, as monotherapy and in combination with a standard chemoimmunotherapy regimen: rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in pediatric and young adult parti...

DRUG: Obinutuzumab

DRUG: Glofitamab

DRUG: Rituximab

DRUG: Ifosfamide

DRUG: Carboplatin

DRUG: Etoposide

DRUG: Tocilizumab

Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leu...
Background: - Some people with cancer have solid tumors. Others have refractory leukemia. This may not go away after treatment. Researchers want to see if a drug called TURALIO(R) can shrink tumors or stop them from growing. Objectives: - To find ...

DRUG: TURALIO(R)

Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved...
This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer in response to treatment (complete response) or a ...

PROCEDURE: Cognitive Assessment

BIOLOGICAL: Obinutuzumab

OTHER: Quality of Life Assessment

Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy
The purpose of the study is to evaluate whether receiving the pneumococcal 13-valent conjugate vaccine (PCV13) before and after CD19-targeted CAR T cell therapy will optimize cellular and humoral immunity to pneumococcus.

BIOLOGICAL: Pneumococcal conjugate vaccine (PCV13)

BIOLOGICAL: CD19 targeted CAR T Cell Therapy

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug CS5001 in patients with advanced hematological and solid tumors.

DRUG: CS5001

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alter...
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by...

DRUG: Oral repotrectinib (TPX-0005)

Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)
This is an open label, single arm, single-center, pilot study of concurrent phototherapy and POTELIGEO (mogamulizumab-kpkc) in early-stage mycosis fungoides.

DRUG: Mogamulizumab-Kpkc

DEVICE: Phototherapy

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab V...
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II ...

PROCEDURE: Biospecimen Collection

BIOLOGICAL: Bleomycin Sulfate

DRUG: Brentuximab Vedotin

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

DRUG: Dacarbazine

DRUG: Doxorubicin Hydrochloride

DRUG: Etoposide

DRUG: Etoposide Phosphate

OTHER: Fludeoxyglucose F-18

RADIATION: Involved-site Radiation Therapy

PROCEDURE: Magnetic Resonance Imaging

BIOLOGICAL: Nivolumab

PROCEDURE: Positron Emission Tomography

DRUG: Prednisolone

DRUG: Prednisone

DRUG: Procarbazine Hydrochloride

OTHER: Questionnaire Administration

DRUG: Vinblastine Sulfate

DRUG: Vincristine Sulfate

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient S...
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Classic Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. The purpose of this study is to assess th...

DRUG: Epcoritamab

UCD19 CAR T Therapy in Adults with B-ALL and MRD Positivity in CR1
This open-label, single arm Phase I trial aims to determine the safety and tolerability of anti-CD19 chimeric antigen receptor-expressing (CAR) T cells (UCD19 CAR T) in adults B-ALL that are in first complete remission with minimal residual disease (...

DRUG: CD19 Directed CAR T Cell

Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors
Background: - Researchers want to develop better ways to treat cancer. In this study, they will give people with cancer two drugs. These drugs have been used on their own to treat some blood cell cancers. Objectives: - To test the safety and effic...

DRUG: Bortezomib plus Clofarabine

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune ...
This study will evaluate the use of siltuximab to decrease the severity of cytokine release syndrome (CRS) and immune effector cell-associated neurological syndrome (ICANS) in patients who will receive chimeric antigen receptor (CAR) T-cell therapy f...

DRUG: Siltuximab

A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
This is a clinical trial to evaluate the feasibility and safety of giving tazemetostat followed by standard of care CAR T cell infusion in previously treated diffuse large b-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (M...

DRUG: Tazemetostat Pill

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)
Background: Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are blood cancers that affect certain white blood cells. Advanced forms of these diseases are difficult to treat. CD19 is a protein often found on the surfaces of th...

BIOLOGICAL: Autologous HuCD19 ( Anti-CD19)CAR T cells

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Rituximab

A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With ...
The purpose of this study is to evaluate the safety and pharmacokinetics of eflapegrastim in pediatric participants with solid tumors or lymphoma and treated with myelosuppressive chemotherapy.

DRUG: Eflapegrastim

DRUG: Chemotherapy

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating P...
This phase II trial studies how well blinatumomab, inotuzumab ozogamicin, and combination chemotherapy work as frontline therapy in treating patients with B acute lymphoblastic leukemia. Immunotherapy with monoclonal antibodies, such as blinatumomab,...

BIOLOGICAL: Blinatumomab

DRUG: Cyclophosphamide

DRUG: Cytarabine

DRUG: Dexamethasone

DRUG: Doxorubicin Hydrochloride

BIOLOGICAL: Inotuzumab Ozogamicin

OTHER: Laboratory Biomarker Analysis

DRUG: Mercaptopurine

DRUG: Methotrexate

BIOLOGICAL: Ofatumumab

DRUG: Prednisone

BIOLOGICAL: Rituximab

DRUG: Vincristine Sulfate

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp ...
This is a phase I/II, open-label, dose-escalation study designed to evaluate the safety, tolerability, and efficacy of englumafusp alfa (RO7227166) in participants with relapsed/refractory Non-Hodgkin's Lymphoma (r/r NHL). Englumafusp alfa will be ad...

DRUG: Englumafusp alfa

DRUG: Obinutuzumab

DRUG: Glofitamab

DRUG: Tocilizumab

CD22 Redirected Autologous T Cells for ALL
This is a pilot study to determine the feasibility and safety of a single dose of autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCR-ζ and 4-1BB signaling domains (CART22/CART22-65s cells) in pediatric and young adult...

BIOLOGICAL: Cohort 1

BIOLOGICAL: Cohorts 2

BIOLOGICAL: Cohort 3

Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizuma...
This study will evaluate the safety and efficacy of favezelimab (MK-4280) in combination with pembrolizumab (MK-3475) using a non-randomized study design in participants with the following hematological malignancies: * classical Hodgkin lymphoma (cH...

BIOLOGICAL: pembrolizumab

BIOLOGICAL: Favezelimab

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma.

DRUG: pembrolizumab

DRUG: gemcitabine

DRUG: vinorelbine

DRUG: liposomal doxorubicin

PROCEDURE: Stem cell mobilization and collection

Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lym...
The proposed study is an open-label, single arm phase II study of venetoclax in combination with rituximab in patients over the age of 60 with previously untreated mantle cell lymphoma. The primary objective of the trial is to determine whether the c...

DRUG: Venetoclax Oral Tablet [Venclexta]

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
This is a research study to determine the safety and tolerability of ATLCAR.CD30 for treating relapsed/refractory Peripheral T Cell Lymphoma. Blood samples will be collected from study participants and the immune T cells will be separated. T cells wi...

BIOLOGICAL: ATLCAR.CD30 T cells

DRUG: Bendamustine

DRUG: Fludarabine

DRUG: Cyclophosphamide

Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous Syst...
This study is being conducted to evaluate the safety and efficacy of the combination of pemetrexed and zanubrutinib (called induction therapy) followed by zanubrutinib treatment alone (also called maintenance therapy) in people who have relapsed or r...

DRUG: Pemetrexed

DRUG: Zanubrutinib

PROCEDURE: Autologous Stem Cell Transplant (ASCT)

RADIATION: Whole Brain Radiation Therapy (WBRT)

BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL
A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

BIOLOGICAL: BAFFR-CAR T cells

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute...
The purpose of this study is to learn more about LP-118 (an experimental drug) and its side effects and decide on acceptable doses. The purpose of this study is to determine if LP-118 can be given safely with another medicine called ponatinib, that i...

DRUG: LP-118

DRUG: Ponatinib

DRUG: Vincristine

DRUG: Dexamethasone

DRUG: Methotrexate

Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, S...
This phase II trial studies how well atezolizumab, obinutuzumab, and venetoclax work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma or Richter syndrome that has come back (recurrent) or does not respond to treatm...

DRUG: Atezolizumab

OTHER: Laboratory Biomarker Analysis

BIOLOGICAL: Obinutuzumab

DRUG: Venetoclax

Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-...
Bruton's tyrosine kinase inhibitors (BTKi), anti-CD20 antibodies, and the B cell lymphoma 2 inhibitor (BCL-2i) venetoclax are drug classes used to treat patients with chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL). Anti-CD20 therap...

DRUG: Zanubrutinib Pill

DRUG: Venetoclax Pill

DRUG: Obinutuzumab Injection

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly ...
This phase I/II trial tests the safety and effectiveness of glofitamab (with obinutuzumab pretreatment), venetoclax, and lenalidomide in treating patients with newly diagnosed, high risk mantle cell lymphoma. Glofitamab and obinutuzumab are monoclona...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

BIOLOGICAL: Glofitamab

DRUG: Lenalidomide

BIOLOGICAL: Obinutuzumab

PROCEDURE: Positron Emission Tomography

DRUG: Venetoclax

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Ther...
To learn about the safety of a drug called axicabtagene ciloleucel given in combination with radiation therapy to patients with relapsed/refractory FL.

DRUG: Axicabtagene Ciloleucel

DRUG: Cyclophosphamide

DRUG: Fludarabine phosphate

DRUG: Prednisone

DRUG: Diphenhydramine

DRUG: Acetaminophen

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD2...
This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Malignancies.

DRUG: AZD5492

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patient...
This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients with hematologic diseases. Giving chemotherapy, such as cyclophosp...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspirate

DRUG: Cyclophosphamide

DRUG: Cyclosporine

PROCEDURE: Diagnostic Imaging

PROCEDURE: Echocardiography

DRUG: Fludarabine Phosphate

PROCEDURE: Multigated Acquisition Scan

DRUG: Mycophenolate Mofetil

OTHER: Survey Administration

DRUG: Thiotepa

RADIATION: Total-Body Irradiation

PROCEDURE: Umbilical Cord Blood Transplantation

Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
The addition of targeted immunotherapy will be safe and well tolerated and facilitate the reduction of anthracycline exposure while preserving lymphoma disease control in children, adolescents and young adults (CAYA) with mature B-cell non-Hodgkin ly...

DRUG: DOC Group B

DRUG: Pv-COMRAD 1 and 2 Group B

DRUG: Pv-R-CYM 1 and 2 Group B

DRUG: DOC Group C

DRUG: MAD CPR 1 and 2

DRUG: Pv-R CYVE 1 and 2

DRUG: Pv-R CYVE-MTX 1 and 2

DRUG: MAD CP

DRUG: Pv-Cytarabine/etoposide

DRUG: AD CP

DRUG: Bv-AVD-R 1 and 2: COHORT IIa

DRUG: Bv-NVD-R, Cycle 1-2

DRUG: Bv-NVD-R, Cycle 1-4 SER

DRUG: Bv-AVD-R

DRUG: Bv-NVD-R, Cycle 1-4 RER

DRUG: Bv-NAVD-R, Cycle 1-2

RADIATION: Involved Site Radiation Therapy

Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refr...
This phase II trial studies how well inotuzumab ozogamicin and blinatumomab work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back, or does not respond to treatment. Immunotherapy wi...

BIOLOGICAL: Blinatumomab

BIOLOGICAL: Inotuzumab Ozogamicin

Zanubrutinib in Combination with R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Ly...
This phase Ib trial seeks to find out the best dose and possible side effects and/or benefits of zanubrutinib in combination with the R-PolaCHP in treating patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Zanubrutinib is designed ...

DRUG: Cyclophosphamide

DRUG: Doxorubicin Hydrochloride

DRUG: Prednisone

BIOLOGICAL: Rituximab

DRUG: Vincristine Sulfate

DRUG: Zanubrutinib

Acalabrutinib in CNSL
This research study is a Phase 1/2 clinical trial testing the safety, tolerance and efficacy of the drug Acalabrutinib for people with recurrent or refractory central nervous system lymphoma (CNSL).

DRUG: Acalabrutinib

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malign...
This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation for hematologic malignancies.

BIOLOGICAL: OrcaGraft (Orca-Q)

Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
This study is being done to examine the safety and effectiveness of pirtobrutinib combined with venetoclax as a possible treatment for participants with Waldenström Macroglobulinemia (WM). The names of the study drugs involved in this study are: * ...

DRUG: Pirtobrutinib

DRUG: Venetoclax

A Study of Radiation Therapy Before CAR T Cell Therapy for People with B Cell Lymphoma
The purpose of this study is to test whether radiation therapy given before standard CAR T cell therapy is a safe and effective treatment for people with relapsed and refractory B cell lymphoma. The researchers will also study whether radiation thera...

RADIATION: Bridging radiotherapy (BRT)

DRUG: Conditioning chemotherapy

BIOLOGICAL: CAR T-cell product

Avo in R/R and Previously Untreated MCL
This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax, and obinutuzumab - as a possible treatment for relapsed or refractory and untreated mantle cell lymphoma (MCL). The names of the study drugs involved in th...

DRUG: Acalabrutinib

DRUG: Venetoclax

DRUG: Obinutuzumab

A Safety Study of SGN-35C in Adults With Advanced Cancers
This clinical trial is studying lymphoma. Lymphoma is a cancer that starts in the blood cells that fight infection. There are several types of lymphoma. This study will enroll people who have classical Hodgkin lymphoma (cHL), peripheral T cell lympho...

DRUG: SGN-35C

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
The goal of this clinical study is to learn more about the safety and dosing of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.

DRUG: Cyclophosphamide

DRUG: Fludarabine

BIOLOGICAL: KITE-363

BIOLOGICAL: KITE-753

Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy
This is a multicenter Phase 1b study evaluating the safety, tolerability, and preliminary anti-tumor activity of NT-I7 administration following standard of care CD19 CAR T-cell therapy for eligible subjects with r/r LBCL.

DRUG: Efineptakin alfa

DRUG: Tisagenlecleucel

DRUG: Axicabtagene ciloleucel

DRUG: Lisocabtagene Maraleucel

Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantat...
This phase II trial studies how well total marrow and lymphoid irradiation works as a conditioning regimen before hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute leukemia. Total body irradiation can lower the rel...

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Fludarabine Phosphate

BIOLOGICAL: Granulocyte Colony-Stimulating Factor

PROCEDURE: Hematopoietic Cell Transplantation

PROCEDURE: Intensity-Modulated Radiation Therapy

DRUG: Mycophenolate Mofetil

DRUG: Tacrolimus

A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
The purpose of this study is to find out whether the study drug mogamulizumab is effective in preventing the development of adult T-cell leukemia/lymphoma (ATL) in people who are at higher risk for this type of cancer because they are infected with t...

DRUG: Mogamulizumab

Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone ...
BrUOG-401 is a prospective, single-arm, phase 2 trial of first-line therapy in adult patients with previously untreated FL or MZL. All patients will be assigned the same initial treatment plan, modified by interim response assessment (IRA) after Cycl...

DRUG: Mosunetuzumab

DRUG: Lenalidomide

A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed...
Patients with relapsed or refractory leukemia or lymphoma are often refractory to further chemotherapy. In this study, the investigators will attempt to use T cells obtained directly from the patient, which can be genetically engineered to express a ...

BIOLOGICAL: SCRI-CAR22v2

Personalized NK Cell Therapy in CBT
This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in treating patients with myelodysplastic syndrome, leukemia, lymphoma or multiple myeloma. This ...

BIOLOGICAL: Allogeneic Natural Killer Cell Line NK-92

BIOLOGICAL: Anti-Thymocyte Globulin

DRUG: Busulfan

DRUG: Clofarabine

DRUG: Cyclophosphamide

DRUG: Fludarabine Phosphate

OTHER: Laboratory Biomarker Analysis

DRUG: Melphalan

BIOLOGICAL: Rituximab

RADIATION: Total-Body Irradiation

PROCEDURE: Umbilical Cord Blood Transplantation

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
This research is being done to assess the effectiveness and safety of acalabrutinib combined with lisocabtagene maraleucel (liso-cel) for people with relapsed/refractory aggressive B-cell lymphoma. This research study involves the study drug acalabr...

DRUG: ACALABRUTINIB

DRUG: LISOCABTAGENE MARALEUCEL

DRUG: Lymphodepleting chemotherapy

Brentuximab Vedotin and Nivolumab for the Treatment of Patients with Relapsed/refractory Classical H...
This phase II trial investigates how well brentuximab vedotin and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back after initial treatment (relapsed) or has not responded to initial treatment (refractory). Brentu...

DRUG: Brentuximab Vedotin

BIOLOGICAL: Nivolumab

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-...
The goal of this study is to evaluate the pharmacokinetics (PK), safety, and efficacy of APG-115 as a single agent or in combination with APG-2575 in patients with T-PLL and NHL.

DRUG: APG-115

DRUG: APG-2575

Phase 2 Study of AFM13 in Combination with AB-101 in Subjects with R/R HL and CD30+ PTCL
AFM13-203 is a phase 2, open-label, multi-center, multi-cohort study with a safety run-in followed by expansion cohorts. The study is evaluating the safety and efficacy of AFM13 in combination with AB-101 in subjects with R/R classical HL and CD30-po...

DRUG: AFM13

DRUG: AB-101

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Interleukin-2

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Pa...
The goal of this clinical study is to compare the study drug, axicabtagene ciloleucel, versus standard of care (SOC) in first-line therapy in participants with high-risk large B-cell lymphoma.

BIOLOGICAL: Axicabtagene Ciloleucel

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Etoposide

DRUG: Rituximab

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Prednisone

Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemi...
This phase II trial studies how well pirtobrutinib and venetoclax work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. This study also seeks to adopt a blood test which shows a small number of cancer cells in the...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

PROCEDURE: Magnetic Resonance Imaging

DRUG: Pirtobrutinib

PROCEDURE: Positron Emission Tomography

DRUG: Venetoclax

PROCEDURE: Echocardiography

PROCEDURE: Multigated Acquisition Scan

A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or H...
The purpose of this study is to find out whether IV injection of HCB101 is an effective treatment for different types of advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma and what side effects (unwanted effects) may occur in subje...

DRUG: HCB101

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab ...
To learn if cyclophosphamide, vincristine, and dexamethasone (called mini hyper-CVD) in combination with intrathecal (delivered into the spine) chemotherapy (methotrexate, hydrocortisone, cytarabine) and compressed rituximab, blinatumomab, and inotuz...

DRUG: Cyclophosphamide

DRUG: Vincristine

DRUG: Blinatumomab

DRUG: Methotrexate

DRUG: Cytarabine

DRUG: Mercaptopurine

DRUG: Prednisone

DRUG: Pegfilgrastim

DRUG: Inotuzumab ozogamicin

DRUG: Rituximab

DRUG: Dexamethasone

Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People Wit...
This study will find out whether people with CLL or SLL who have received treatment with venetoclax, either alone or in combination with another drug, and who are found to be MRD-negative, can stop treatment with venetoclax and remain off-treatment f...

DRUG: Venetoclax monotherapy

DRUG: Venetoclax with anti CD20 monoclonal antibody

Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome
The purpose of this study is to determine the efficacy of the combination of LD-TSEBT and mogamulizumab in patients with MF and SS. And to evaluate the secondary measures of clinical benefit of the combination therapy and to evaluate the safety and t...

DRUG: Mogamulizumab

RADIATION: LD TSEBT

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin ...
Patients will receive one of two conditioning regimens (BEAM or CBV) before receiving an autologous stem cell transplant (ASCT). If patients achieve either complete, partial, or stable response following ASCT, they will receive an IV dose of Polatuzu...

DRUG: Polatuzumab vedotin

A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
This phase 1 study will investigate the safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity of AZD0486, a CD19 x CD3 T-cell engaging bispecific antibody, in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (B...

DRUG: AZD0486 IV

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
This is a first in human, Phase 1/2 open-label multi-center, dose escalation and expansion study to evaluate the safety, tolerability, PK, PD and efficacy of RNK05047 when administered an intravenous (IV) infusion to subjects with advanced solid tumo...

DRUG: RNK05047

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
The purpose of the study is to establish the safety and efficacy of zanubrutinib in combination with rituximab for people with untreated B-cell lymphomas (marginal zone lymphoma and follicular lymphomas).

DRUG: Zanubrutinib

DRUG: Rituximab

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
This phase I trial tests the safety, side effects and best dose of CC-99282 with rituximab for the treatment of patients who have received chimeric antigen receptor (CAR) T cell therapy for non-Hodgkins lymphoma and in whom have had a sub-optimal res...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

DRUG: Golcadomide

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Rituximab

Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT ...
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (m...

DRUG: Tirabrutinib

DRUG: Tirabrutinib

DRUG: Tirabrutinib

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoi...
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with t...

PROCEDURE: Biospecimen Collection

PROCEDURE: Dual X-ray Absorptiometry

DRUG: Tegavivint

PROCEDURE: X-Ray Imaging

A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR Aft...
To learn if loncastuximab tesirine (called "lonca" in this informed consent form) can help to control large B-cell lymphoma that is relapsed or refractory after receiving CAR T-cell therapy. The safety and possible effects of the study therapy will a...

DRUG: Loncastuximab Tesirine

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation from Chronic Ly...
This phase II trial tests whether acalabrutinib, venetoclax, and durvalumab work in treating patients with Richter transformation from chronic lymphocytic leukemia or small lymphocytic lymphoma. Richter transformation is a rare condition in which chr...

DRUG: Acalabrutinib

BIOLOGICAL: Durvalumab

DRUG: Venetoclax

A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R...
This is a Phase 1, open-label, multicenter study. This will be the first-in-human clinical study for ONO-7018 and will be conducted in two phases: a Dose Escalation Phase (Part 1) and a Dose Expansion Phase (Part 2).

DRUG: ONO-7018

DRUG: ONO-7018

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-A...
This is a Phase 2 Study is to determine the efficacy and safety rate of B-Cell Acute Lymphoblastic Leukemia (B-ALL) participants in remission with minimal residual disease (MRD) after KTE-X19 CAR T-cell therapy

DRUG: Tecartus

A Study of JNJ-90014496 in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
This is a Phase Ib multicenter, open-label study of JNJ-90014496, an autologous bi-specific chimeric antigen receptor (CAR) T-cell therapy, targeting both cluster of differentiation (CD) CD19 and CD20 for the treatment of adult participants with rela...

BIOLOGICAL: JNJ-90014496

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.

DRUG: Docirbrutinib

A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
The Phase 1 part of the study is a dose escalation of STP938 as monotherapy. The Phase 2 part of the study is cohort expansion of STP938 as a monotherapy in 5 different B and T cell lymphomas.

DRUG: STP938

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus (VSV) carrying the human (h) sodium iodide symporter (NIS) and Interferon (IFN) beta (β) genes (VSV-hIFNβ-NIS) in combination with ipilimumab and cemi...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter

PROCEDURE: Single Photon Emission Computed Tomography

BIOLOGICAL: Cemiplimab

BIOLOGICAL: Ipilimumab

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Media...
This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as ...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

DRUG: Doxorubicin Hydrochloride

PROCEDURE: Echocardiography

DRUG: Etoposide Phosphate

BIOLOGICAL: Filgrastim

PROCEDURE: Lumbar Puncture

BIOLOGICAL: Nivolumab

BIOLOGICAL: Pegfilgrastim

PROCEDURE: Positron Emission Tomography

DRUG: Prednisolone

DRUG: Prednisone

RADIATION: Radiation Therapy

BIOLOGICAL: Rituximab

BIOLOGICAL: Rituximab and Hyaluronidase Human

DRUG: Vincristine Sulfate

Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
This research study is studying if the investigational drug, Pembrolizumab, in combination with chemotherapy helps primary central nervous system lymphoma with acceptable side effects. This research study involves a combination of the below drugs: ...

DRUG: Pembrolizumab

DRUG: Methotrexate

DRUG: Temozolomide

DRUG: Rituximab

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Follow...
This phase I trial studies the safety and side effects of cytomegalovirus (CMV) specific CD19-chimeric antigen receptor (CAR) T-cells along with the CMV-modified vaccinia Ankara (MVA) triplex vaccine following a stem cell transplant in treating patie...

BIOLOGICAL: Anti-CD19-CAR CMV-specific T-lymphocytes

PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation

BIOLOGICAL: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine

PROCEDURE: Myeloablative Conditioning

CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
The study participant has one of the following blood cancers: acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (B-ALL, T-ALL) or Lymphoma. Your cancer has been difficult to treat (refractory) or has come b...

DRUG: Fludarabine

DRUG: Cyclophosphamide

DRUG: CD70-CAR T cell infusion (Autologous)

DRUG: Mesna

Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides
Mycosis fungoides (MF) is the most common subtype of cutaneous T cell lymphoma (MF) and presents as cutaneous patches, plaques, and tumors. Radiation therapy (RT) is a frequently pursued management option for CTCL, especially in patients with more ad...

DRUG: Imiquimod

RADIATION: Radiation Therapy

Umbilical Cord Blood Transplantation From Unrelated Donors
This study is a single-center, treatment protocol with 4 possible preparative regimens, designed to validate the process of umbilical cord blood stem cell transplantation at our institution.

RADIATION: Total Body Irradiation 1200 cGy

RADIATION: Total Body Irradiation 200 cGy

DRUG: Cyclophosphamide

DRUG: Mesna

PROCEDURE: Cord Blood Infusion

DRUG: Busulfan

DRUG: Fludarabine

DRUG: Melphalan

A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of Hi...
This study is planned as a single arm clinical trial of tazemetostat in combination with bendamustine and rituximab with both a phase I and phase II component. All patients will receive tazemetostat twice daily on days 1-28 in combination with bendam...

DRUG: Bendamustine

DRUG: Rituximab

DRUG: Tazemetostat

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission ...
This phase II trial compares epcoritamab to standard practice (observation) for the treatment of patients with B-cell lymphomas who are not in complete remission after treatment with CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy. Epc...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

BIOLOGICAL: Epcoritamab

PROCEDURE: Magnetic Resonance Imaging

OTHER: Patient Observation

PROCEDURE: Positron Emission Tomography

Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+...
This phase II pilot trial studies how well brentuximab vedotin with or without nivolumab works in treating patients with CD30+ lymphoma that has come back after a period of improvement or does not respond to treatment. Biological therapies, such as b...

DRUG: Brentuximab Vedotin

OTHER: Laboratory Biomarker Analysis

BIOLOGICAL: Nivolumab

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Rela...
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) ma...

DRUG: Obinutuzumab

DRUG: Glofitamab

DRUG: Rituximab

DRUG: Bendamustine

DRUG: Lenalidomide

DRUG: Tocilizumab

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relap...
To learn if giving mosunetuzumab in combination with polatuzumab vedotin, tafasitamab, and lenalidomide can help to control relapsed/refractory FL and DLBCL.

DRUG: Mosunetuzumab

DRUG: Polatuzumab vedotin

DRUG: Tafasitamab

DRUG: Lenalidomide

Study of SGR-1505 in Mature B-Cell Neoplasms
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

DRUG: SGR-1505

Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
The purpose of the study is to assess the safety and efficacy of once daily itacitinib oral administration in participants with diffuse large B-cell lymphoma (DLBCL) who will receive CAR-T cell therapy with axicabtagene ciloleucel (axi-cel).

DRUG: Itacitinib

BIOLOGICAL: Chimeric antigen receptor (CAR) T-cell therapy

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells. This research study involves the study drugs:...

DRUG: CD79b-19 CAR T cells

DRUG: Cyclophosphamide

DRUG: Fludarabine

Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Sy...
The purpose of this study is to find out whether the combination of pembrolizumab and gemcitabine is an effective treatment for mycosis fungoides and Sézary syndrome.

DRUG: Gemcitabine

DRUG: Pembrolizumab

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patient...
This open-label, single arm phase 1/1b trial aims to determine the safety and tolerability of anti-CD19 and anti-CD22 chimeric antigen receptor-expressing (CAR) T cells (CD19x22 CAR T) in adolescents and adults with relapsed/refractory (R/R) B-cell N...

DRUG: CD19x22 CAR T Cells

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR...
Background: Aggressive B-cell lymphomas can be cured but people with disease that resists treatment or that returns after treatment have poor outcomes with standard therapies. Indolent B-cell lymphomas are generally incurable with standard therapy a...

BIOLOGICAL: obinutuzumab

DRUG: prednisone

DRUG: Revlimid

BIOLOGICAL: Polatuzumab

DRUG: ibrutinib

DRUG: venetoclax

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Ly...
This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a t...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

BIOLOGICAL: Mosunetuzumab

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Rituximab

BIOLOGICAL: Rituximab and Hyaluronidase Human

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Ac...
This phase II trial investigates two strategies and how well they work for the reduction of graft versus host disease in patients with acute leukemia or MDS in remission. Giving chemotherapy and total-body irradiation before a donor peripheral blood ...

RADIATION: Total-Body Irradiation

DRUG: Thiotepa

DRUG: Fludarabine

DRUG: Tacrolimus

BIOLOGICAL: Allogeneic CD34+-enriched and CD45RA-depleted PBSCs

DRUG: Methotrexate

DRUG: Cyclophosphamide

BIOLOGICAL: Peripheral Blood Stem Cell

DRUG: Cyclosporine

DRUG: Sirolimus

DRUG: Busulfan

PROCEDURE: Bone Marrow Aspiration and Biopsy

PROCEDURE: Echocardiography

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Biospecimen Collection

Ritlecitinib in CTCL
The purpose of this research study is to evaluate the effectiveness and safety of Ritlecitinib in skin and blood in persons with Cutaneous T-Cell Lymphoma (CTCL). CTCL is a rare type of cancer that starts in the white blood cells and eventually can r...

DRUG: Ritlecitinib

A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
This study evaluates the safety, pharmacokinetics, and efficacy of BP1002 (L-Bcl-2) antisense oligonucleotide in patients with advanced lymphoid malignancies. Up to 12 evaluable patients with a diagnosis of relapsed or refractory lymphoid malignancie...

DRUG: L-Bcl-2 antisense oligonucleotide

Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma
The goal of this clinical trial is to learn about treatment for people with B-cell lymphoma that did not respond to treatment or that has gotten worse after treatment. The aim of this trial is to answer the following questions: * If it is realistic ...

RADIATION: Bridging radiation therapy

BIOLOGICAL: Liso-cel

RADIATION: Post-infusion radiation

A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenou...
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). This study will assess how safe and effective epcoritamab plus lenalidomide (E-Len) is compared to rituximab plus gem...

DRUG: Epcoritamab

DRUG: Rituximab

DRUG: Lenalidomide

DRUG: Oxaliplatin

DRUG: Gemcitabine

Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL
The purpose of this study is to find out whether the combination treatment of romidepsin and oral azacytidine is safe and effective in patients with Peripheral T-Cell Lymphoma (PTCL). This study will compare the experimental combination treatment of ...

DRUG: Azacytidine

DRUG: Romidepsin

DRUG: Belinostat

DRUG: Pralatrexate

DRUG: Gemcitabine

Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Di...
This early phase I trial investigates how well duvelisib exposure before CAR-T cell manufacturing works to enhance immune profiles of T cells in patients with diffuse large B-cell lymphoma that has come back (recurrent) or does not respond to treatme...

DRUG: Duvelisib

BIOLOGICAL: Tisagenlecleucel

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Dis...
This is a treatment guideline for an unrelated umbilical cord blood transplant (UCBT) using a myeloablative preparative regimen for the treatment of hematological diseases, including, but not limited to acute leukemias. The myeloablative preparative ...

DRUG: Fludarabine

DRUG: Cyclophosphamide

RADIATION: Total Body Irradiation

DRUG: Cyclosporine A

DRUG: Mycophenylate mofetil

BIOLOGICAL: Umbilical cord blood

Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With ...
This phase II trial compares mosunetuzumab to the usual treatment (rituximab) for improving survival in patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Rituximab and mosunetuzumab are monoclonal antibodies. They bind to a prote...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

OTHER: Fludeoxyglucose F-18

BIOLOGICAL: Mosunetuzumab

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Rituximab

BIOLOGICAL: Rituximab and Hyaluronidase Human

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimisation study of AZD0486 to evaluate the safety, tolerability, and efficacy of AZD0486 monotherapy in participants with R/R B ALL who have received ≥ 2 pri...

DRUG: AZD0486

PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated with Antibody Therapy, Checkpoint Inhibit...
This phase II trial studies the effect of brentuximab vedotin and nivolumab alone and in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone in treating patients with untreated, stage I-IV primary mediastinal large B-cell lympho...

DRUG: Brentuximab Vedotin

DRUG: Cyclophosphamide

DRUG: Doxorubicin

BIOLOGICAL: Nivolumab

DRUG: Prednisone

OTHER: Quality-of-Life Assessment

BIOLOGICAL: Rituximab

Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma
This phase II clinical trial studies the combination of mosunetuzumab and polatuzumab vedotin in order to see how well it works in patients with untreated follicular lymphoma. Mosunetuzumab is an antibody that has been engineered to attach to two tar...

DRUG: Mosunetuzumab

DRUG: Polatuzumab vedotin

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for th...
This phase I trial studies the safety and feasibility of cytomegalovirus (CMV) specific CD19-chimeric antigen receptor (CAR) T cells in combination with the CMV-modified vaccinia Ankara (MVA) triplex vaccine following lymphodepletion in treating pati...

BIOLOGICAL: Anti-CD19-CAR CMV-specific T-lymphocytes

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

PROCEDURE: Leukapheresis

PROCEDURE: Lymphodepletion Therapy

PROCEDURE: Magnetic Resonance Imaging

BIOLOGICAL: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine

PROCEDURE: Positron Emission Tomography

PROCEDURE: X-Ray Imaging

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell...
This is a Phase Ib study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in pediatric patients with relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B ALL) an...

BIOLOGICAL: AUTO1

A Study of Oral 7HP349 (Alintegimod) in Combination with Ipilimumab Followed by Nivolumab Monotherap...
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the Phase 2a pr...

DRUG: Alintegimod

DRUG: Ipilimumab

DRUG: Nivolumab

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Pa...
To learn if the combination of pirtobrutinib (also called LOXO-305) and venetoclax can help to control mantle cell lymphoma (MCL) that is relapsed (has come back) or refractory (has not responded to therapy).

DRUG: Pirtobrutinib

DRUG: Venetoclax

Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
This is a first in children prospective study of allogeneic hematopoietic cell transplant using a centrally manufactured engineered donor graft (Orca-Q). The study will assess safety and efficacy of Orca-Q in pediatric patients with hematologic malig...

BIOLOGICAL: Orca-Q

A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma
This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, pharmacogenomics, and efficacy of CYC140 administered orally daily. This study consists of Phase 1 and Phase...

DRUG: CYC140

A Study of DSP-5336 in Relapsed/refractory AML/ ALL with or Without MLL Rearrangement or NPM1 Mutati...
A Phase 1/2 dose escalation / dose expansion study of DSP 5336 in patients with relapsed or refractory AML.

DRUG: DSP-5336

Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic ...
This phase II trial tests how well tafasitamab and zanubrutinib works in treating patients with newly diagnosed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Tafasitamab is a monoclonal antibody that may interfere with the abil...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

BIOLOGICAL: Tafasitamab

DRUG: Zanubrutinib

A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lympho...
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractory to Rituximab

BIOLOGICAL: BI-1206

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukem...
This phase II trial studies the side effects and how well combination chemotherapy works in treating patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, Burkitt lymphoma/leukemia, or double-hit lymphoma/leukemia that has come back or ...

DRUG: Bortezomib

DRUG: Clofarabine

DRUG: Cyclophosphamide

DRUG: Dexamethasone

DRUG: Etoposide

BIOLOGICAL: Ofatumumab

BIOLOGICAL: Pegfilgrastim

BIOLOGICAL: Rituximab

DRUG: Vincristine Sulfate Liposome

A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma
This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, PK, pharmacodynamics, PGx, and efficacy of fadraciclib administered orally BID. This study consists of Phase 1 and Phase 2 components in subject...

DRUG: Fadraciclib

Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients Wit...
This study will assess the safety, efficacy, and feasibility of ⍺/β CD3+ T-cell and CD19+ B-cell depletion in allogeneic stem cell transplantation in patients with acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), juvenile myelomonocyti...

DEVICE: Miltenyi CliniMACS Prodigy ® system

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
This phase I trial tests the safety, side effects, best dose and effectiveness of lenalidomide when added to nivolumab and the usual drugs (rituximab and methotrexate) in patients with primary central nervous system (CNS) lymphoma. Lenalidomide may s...

PROCEDURE: Bone Marrow Aspiration and Biopsy

PROCEDURE: Computed Tomography

PROCEDURE: Echocardiography

DRUG: Lenalidomide

PROCEDURE: Lumbar Puncture

PROCEDURE: Magnetic Resonance Imaging

DRUG: Methotrexate

BIOLOGICAL: Nivolumab

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Rituximab

PROCEDURE: Ultrasound Imaging

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination Wit...
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin, glofitamab, or mosunetuzumab, and to identify the maximum tolerated dose (MTD) and/or recommended do...

DRUG: Loncastuximab Tesirine

DRUG: Polatuzumab Vedotin

DRUG: Glofitamab

DRUG: Mosunetuzumab

DRUG: Obinutuzumab

PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in...
To learn about the effects of brentuximab vedotin and pembrolizumab in combination with doxorubicin and dacarbazine when given to patients who have Stage II cHL with bulky mediastinal disease or advanced cHL (Stage III or IV) and who have not receive...

DRUG: Brentuximab vedotin

DRUG: Doxorubicin Hydrochloride

DRUG: Pembrolizumab

DRUG: Dacarbazine

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic...
This is an open label, multicenter, phase 1/2 dose evaluation and cohort expansion study evaluating the safety and efficacy of CTX131 in subjects with Relapsed/Refractory Hematologic Malignancies

BIOLOGICAL: CTX131

AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refra...
This study is designed to evaluate the safety, tolerability, PK and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.

DRUG: AZD3470

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
The purpose of this study is to test any good and bad effects of the study drug called brentuximab vedotin at a lower dose than is FDA-approved.

DRUG: brentuximab vedotin

DRUG: brentuximab vedotin

DRUG: brentuximab vedotin

A Safety Study of SGN-35T in Adults With Advanced Cancers
This clinical trial is studying lymphoma. Lymphoma is a cancer that starts in the blood cells that fight infections. There are several types of lymphoma. This study will enroll people who have lymphoma, such as classical Hodgkin lymphoma, peripheral ...

DRUG: SGN-35T

A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides
The researchers are doing this study to test the safety of combining bexarotene with TSEB radiotherapy in people who have a common form of CTCL called mycosis fungoides (MF). Bexarotene is a form of vitamin A that activates proteins called retinoid ...

DRUG: Bexarotene

RADIATION: Total Skin Electron Beam (TSEB)

Safe Accelerated Venetoclax Escalation in CLL
This research study is trying to determine which patients with newly diagnosed or relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), as grouped by their risk for tumor lysis syndrome (TLS), are able to safely ...

DRUG: Venetoclax

DRUG: Obinutuzumab

DRUG: Rituximab

Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refrac...
This research study is studying a medication called Venetoclax and a chemotherapy regimen as a possible treatment for Acute Lymphoblastic Leukemia. The drugs involved in this study are: * Venetoclax * Standard Chemotherapy (which includes cyclophos...

DRUG: Venetoclax

DRUG: Standard Chemotherapy

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
This is a phase II study using risk and response-adapted therapy for low, intermediate and high risk classical Hodgkin lymphoma. Chemotherapy regimens will be based on risk group assignment. Low-risk and intermediate- risk patients will be treated wi...

DRUG: bendamustine

DRUG: Etoposide

DRUG: Doxorubicin

DRUG: Bleomycin

DRUG: Vincristine

DRUG: Vinblastine

DRUG: Prednisone

DRUG: Filgrastim

DRUG: Brentuximab Vedotin

DRUG: Cyclophosphamide

DRUG: DTIC

OTHER: Quality of Life Measurements

RADIATION: Radiotherapy

A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
The purpose of this study is to find out whether it is practical to use a newer way to calculate melphalan dose given (called population PK model) in BEAM chemotherapy before AHCT. Standard dose is fixed for everybody and is calculated using height a...

OTHER: Pharmacokinetics

OTHER: Pharmacokinetics

Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)
Participants are invited to take part in this research study because they have relapsed (cancer has come back) or refractory (cancer has not responded to treatment) B-cell Lymphoma and will be undergoing CAR T-cell Therapy. This research is being do...

RADIATION: Adaptive Bridging Radiation Therapy (ABRT)

Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies
This is a single arm pilot study for patients using α/β T cell-depleted peripheral Stem Cell Transplantation (PSCT) in with alternative donor sources with hematologic malignancies receiving alternative donor (unrelated or partially matched related) m...

DEVICE: Alpha Beta T cell depletion

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma
Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory lymphoma, however not all tumors respond or remain in response to CD19 targeted CAR-T cells. We posit that CAR-T cells expressing BAFF (BAFF CAR-T cel...

DRUG: BAFF CAR-T

Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refracto...
This phase II trial investigates the side effects of CD19 chimeric antigen receptor (CAR) T cells and acalabrutinib, and to see how well they work in treating patients with mantle cell lymphoma that has come back (relapsed) or does not respond to tre...

DRUG: Acalabrutinib

BIOLOGICAL: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell ...
Background: B-cell lymphoma is a cancer of white blood cells found in the lymph nodes. It affects the system that fights infections and disease. Researchers want to learn how certain drugs work together to treat B-cell lymphomas. The drugs are venet...

DRUG: Venetoclax

DRUG: Ibrutinib

DRUG: Prednisone

BIOLOGICAL: Obinutuzumab

DRUG: Revlimid (lenalidomide)

Acalabrutinib in Combination with Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Ch...
This phase II trial tests whether acalabrutinib in combination with venetoclax or obinutuzumab works to shrink tumors in patients with treatment-naive chronic lymphocytic leukemia . Acalabrutinib is also an inhibitor that works in the body to block t...

DRUG: Acalabrutinib

BIOLOGICAL: Obinutuzumab

DRUG: Venetoclax

SG2501 Safety Study in Subjects With Relapsed or Refractory Hematological Malignancies and Lymphoma.
This is a phase Ia/Ib, first-in-Human, open-Label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of SG2501 in subjects...

DRUG: SG2501

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
This phase II trial tests how well zanubrutinib and lisocabtagene maraleucel (liso-cel) work together in treating patients with Richter's syndrome. Richter's syndrome occurs when chronic lymphocytic leukemia and/or small lymphocytic leukemia transfor...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

DRUG: Fludarabine

PROCEDURE: Leukapheresis

BIOLOGICAL: Lisocabtagene Maraleucel

PROCEDURE: Lymph Node Biopsy

PROCEDURE: Positron Emission Tomography

DRUG: Zanubrutinib

Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or...
This phase II trial studies how well zanubrutinib and rituximab work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma for which the patient has not received treatment in the past (previously untreated). Zanubrutini...

BIOLOGICAL: Rituximab

DRUG: Zanubrutinib

Study of Oral MRT-2359 in Selected Cancer Patients
This Phase 1/2, open-label, multicenter study is conducted in patients with previously treated selected solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), high-grade neuroendocrine cancer of any primary site, d...

DRUG: Oral MRT-2359

DRUG: Oral MRT-2359

DRUG: Oral MRT-2359

DRUG: Oral MRT-2359

DRUG: Oral MRT-2359

DRUG: Oral MRT-2359

Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicu...
The purpose of this research is to see if Loncastuximab Tesirine in combination with Rituximab will result in higher complete response rate when given to treat follicular lymphoma.

DRUG: Loncastuximab tesirine

DRUG: Rituximab

Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
This is a phase 2, open-label, randomized, multicenter clinical trial in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) who meet the criteria for standard-of-care FDA label for CD19 CAR T-cell therapy with brexucabtagene autoleucel ...

DRUG: Pirtobrutinib

DRUG: Brexucabtagene Autoleucel

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MP...
This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 sub...

DRUG: LP-118

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphom...
Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: * Advanced, which means cancer spread in the body or cannot be removed with sur...

BIOLOGICAL: Pembrolizumab

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromos...
This phase II trial studies how well blinatumomab, methotrexate, cytarabine, and ponatinib work in treating patients with Philadelphia chromosome (Ph)-positive, or BCR-ABL positive, or acute lymphoblastic leukemia that has come back or does not respo...

BIOLOGICAL: Blinatumomab

DRUG: Cytarabine

DRUG: Methotrexate

DRUG: Ponatinib

A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Ly...
To learn if response-adapted, ultra-low dose radiation therapy can help to control MZL. This means participates first receive lower does of radiation therapy and then, based on how the disease responds, may receive higher doses after that.

RADIATION: Ultra Low Dose 4 Gy Radiation

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lym...
This phase II trial tests how well tafasitamab, lenalidomide and venetoclax work in treating patients with mantle cell lymphoma that has come back (after a period of improvement) (relapsed) or that has not responded to previous treatment (refractory)...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Lenalidomide

PROCEDURE: Lumbar Puncture

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Tafasitamab

DRUG: Venetoclax

Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Pa...
This phase II trial studies how well ultra low dose radiation works before or after chemotherapy-free targeted therapy in treating patients with mantle cell lymphoma that has come back or does not respond to treatment. Radiation therapy uses high ene...

DRUG: Low Dose Radiation Therapy

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Ho...
Background: The drug Nivolumab has been approved to treat some cancers. Researchers want to see if it can slow the growth of other cancers. They want to study its effects on cancers that may have not responded to chemotherapy or other treatments. O...

BIOLOGICAL: Nivolumab

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the grow...

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Prednisone

DRUG: Etoposide

DRUG: Duvelisib

DRUG: Oral azacitidine

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through th...
Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, pharmacokinetics, and preliminary efficacy of ABBV-101 in adult partici...

DRUG: ABBV-101

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Pl...
The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymp...

DRUG: Relatlimab

DRUG: Nivolumab

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells with Chimeric...
The study is designed to examine the feasibility and safety of collecting autologous hematopoietic stem cells (HSCs) to be combined with CAR T-cell therapy for patients with relapsed/refractory (r/r) hematological disease. The study will evaluate fea...

BIOLOGICAL: autologous hematopoietic stem cells added to planned CAR T

Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Oz...
This research study will add an anti-cancer drug (called inotuzumab ozogamicin also known as "InO") to treatment for participants with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Doctors leading this stu...

DRUG: Inotuzumab ozogamicin

DRUG: Dasatinib

DRUG: Dexamethasone

DRUG: Methotrexate

DRUG: Vincristine

DRUG: Ponatinib

DRUG: Methotrexate for Injection

PROCEDURE: Allogenic Stem Cell Transplantation

Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressin...
Patients eligible for this study have a type of blood cancer called T-cell leukemia or lymphoma (lymph gland cancer). The body has different ways of fighting infection and disease. No one way seems perfect for fighting cancers. This research combine...

GENETIC: Autologous CD5.CAR/28zeta CAR T cells

GENETIC: Allogeneic CD5.CAR/28zeta CAR T cells

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Le...
The study is a global, multi-center safety and efficacy trial of epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20). Epcoritamab will either be studied as: * Monotherapy, or * Combination therapy: * epcoritamab + vene...

BIOLOGICAL: Epcoritamab

BIOLOGICAL: Epcoritamab

DRUG: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone

DRUG: Venetoclax

BIOLOGICAL: Epcoritamab

DRUG: Lenalidomide

Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
This phase Ib/II trial studies the side effects and efficacy of maintenance acalabrutinib following cellular therapy in treating patients with large B-cell lymphoma at very high risk of the cancer coming back. Acalabrutinib is a small molecular inhib...

DRUG: Acalabrutinib

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
This is an open-label, single-arm, multicenter, phase II study combining pembrolizumab and mogamulizumab in patients with advanced-stage, relapsed or refractory CTCL Each cycle will equal 6 weeks. Pembrolizumab will be administered on Day 1 of each c...

DRUG: Pembrolizumab

DRUG: Mogamulizumab

A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer are: * can a safe dose of JNJ-90009530 be determined that is safe and well tolerated by p...

DRUG: JNJ-90009530

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Ly...
This phase II trial is to evaluate the effects of acalabrutinib in combination with venetoclax in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma that does not respond to treatment (refractory) or that has come back ...

DRUG: Acalabrutinib

DRUG: Venetoclax

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

PROCEDURE: Magnetic Resonance Imaging

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lympho...
This phase I trial studies the side effects and best dose of venetoclax when given together with lenalidomide and rituximab hyaluronidase in treating patients with follicular lymphoma and marginal zone lymphoma that has come back after treatment (rel...

DRUG: Venetoclax

DRUG: Lenalidomide

BIOLOGICAL: Rituximab

BIOLOGICAL: Rituximab and Hyaluronidase Human

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone...
The goal of this clinical trial is to determine the safety and feasibility of allogeneic transplantation with bone marrow from a deceased donor in patients with acute leukemias. Patients will either receive myeloablative conditioning or reduced inten...

OTHER: Ossium HPC Marrow, Bone Marrow Transplant

OTHER: Pre-transplant conditioning - Myeloablative (MAC)

OTHER: Pre-transplant conditioning - Reduced Intensity (RIC)

OTHER: Post-transplant treatment

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
The purpose of this study is to determine how effective and safe the combination of glofitamab and obinutuzumab is in treating patients with Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) who have not received other treatments for their ly...

DRUG: Obinutuzumab

DRUG: Glofitamab

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymph...
This is a Phase 1b study consisting of 2 parts: a dose escalation (Part 1) of CC-220 or CC-99282 added to the standard R-CHOP-21 regimen for first-line treatment of a-BCL. The dose escalation (Part 1) will consist of 2 parallel arms in combination wi...

DRUG: CC-220

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Prednisone

DRUG: CC-99282

DRUG: Polatuzumab vedotin

DRUG: Rituximab

Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy
While chimeric antigen receptor T-cell (CAR T-cell) therapy produces impressive response rates in heavily pre-treated patients, early loss of response remains a barrier. One potential mechanism of relapse is limited CAR T-cell persistence. Pre-clinic...

DRUG: Duvelisib

A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab ...
This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymp...

DRUG: Odronextamab

DRUG: Lenalidomide

DRUG: Rituximab

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
This is a Phase 1/2a open-label, multicenter, dose escalation and dose expansion trial in which IMT-009 will be administered by the intravenous (IV) route to participants with solid tumors or lymphomas. The main goals of this study are to: * Find t...

DRUG: IMT-009

COMBINATION_PRODUCT: Fruquintinib

Post-Op Pain Control for Prophylactic Intramedullary Nailing.
Nationally, the opioid crisis has become a major epidemic with increasing mortality rates each year. Orthopedic surgeons routinely prescribe narcotics instead of NSAIDs for post-op pain control because of risk of delayed healing and nonunion due to N...

DRUG: Ketorolac

DRUG: Normal saline

DRUG: Acetaminophen

DRUG: Oxycodone Acetaminophen

DRUG: Morphine

DRUG: Hydrocodone/Acetaminophen

DRUG: Oxycodone

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chem...
Subjects with relapsed large cell lymphoma will receive 3 cycles of combination therapy consisting of GDP and epcoritamab. Each cycle will last 21 days. GDP consists of gemcitabine 1000 mg/m2 IV on Days 1 and 8, cisplatin 75 mg/m2 IV on Day 1, and de...

PROCEDURE: AutoSCT OR CAR T-cell Therapy

DRUG: GDP

DRUG: Epcoritamab

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
This research study is evaluating a drug called ABL001 taken in combination with dasatinib (Sprycel®) and prednisone (a steroid) as a possible treatment for B-cell Acute Lymphoblastic Leukemia that is BCR-ABL positive (BCR-ABL+ B-ALL) or Chronic Myel...

DRUG: ABL001

DRUG: Dasatinib

DRUG: Prednisone

DRUG: Blinatumomab

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects ...
This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.

DRUG: DPX-Survivac

DRUG: Pembrolizumab

DRUG: CPA

Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL
This research study is studying a drug called Paxalisib (GDC-0084) as a possible treatment for primary central nervous system lymphoma (PCNSL)

DRUG: PAXALISIB

Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or R...
This is a phase Ib study to establish safety of Axi-Cel-2 in patients with Large B Cell Lymphoma (LBCL) who are at high risk of relapse.

DRUG: Axicabtagene Ciloleucel

Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
The goal of this study is to test SIRPant-M, an autologous cell therapy, alone or in combination with focal external-beam radiotherapy in participants with relapsed or refractory non-Hodgkin's lymphoma (NHL). Two dose levels of SIRPant-M are being te...

BIOLOGICAL: SIRPant-M

RADIATION: External-beam radiotherapy (XRT)

CAR-T Followed by Bispecific Antibodies
The research study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab (Cohort 1) or obinutuzumab and glofitamab (Cohort 2) when given after CAR (genetically modified) T cells. The study is for patients who ...

DRUG: mosunetuzumab

DRUG: glofitamab

DRUG: obinutuzumab

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Ste...
The goal of this phase II clinical study is to learn about the safety of inotuzumab ozogamicin when given with fludarabine, with or without bendamustine, melphalan, and rituximab before and after a stem cell transplant. Researchers also want to learn...

PROCEDURE: Allogeneic Bone Marrow Transplantation

DRUG: Bendamustine

BIOLOGICAL: Filgrastim-sndz

DRUG: Fludarabine

BIOLOGICAL: Inotuzumab Ozogamicin

DRUG: Melphalan

PROCEDURE: Peripheral Blood Stem Cell Transplantation

BIOLOGICAL: Rituximab

DRUG: Tacrolimus

Iomab-ACT: a Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patie...
This is a pilot study; patients will receive 131-I apamistamab prior to CAR T-cell infusion in order to determine the maximum tolerated dose of 131-I apamistamab is exceeded at 75 mCi, and if so, to assess the safety of a step-down dose of 50 mCi.

DRUG: 131-I Apamistamab

BIOLOGICAL: CAR T-cell

Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma
The goal of this study is to learn about the safety and effectiveness of the combination of tazemetostat pills in combination with mosunetuzumab injections for people with follicular lymphoma who haven't received treatment before. The investigators h...

DRUG: Mosunetuzumab

DRUG: Tazemetostat Pill

Photopheresis in Early-stage Mycosis Fungoides
The purpose of this study is to determine whether photopheresis therapy can be used to improve the clinical course of early stage cutaneous T-cell lymphoma (CTCL). Currently, photopheresis is performed as a palliative treatment for late stage CTCL. H...

DRUG: UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis

DEVICE: THERAKOS® CELLEX photopheresis system

An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Eps...
A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas

DRUG: Nanatinostat in combination with valganciclovir

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific A...
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to ch...

DRUG: Palbociclib

DRUG: Sunitinib

DRUG: Temsirolimus

DRUG: Trastuzumab and Pertuzumab

DRUG: Vemurafenib and Cobimetinib

DRUG: Regorafenib

DRUG: Olaparib

DRUG: Pembrolizumab

DRUG: Nivolumab and Ipilimumab

DRUG: Abemaciclib

DRUG: Talazoparib

DRUG: Atezolizumab and PHESGO

DRUG: Atezolizumab and Talazoparib

DRUG: Entrectinib

DRUG: Larotrectinib

DRUG: Tucatinib plus Trastuzumab Subcutaneous (SC)

DRUG: Futibatinib

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With ...
The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of rrDLBCL. T...

BIOLOGICAL: Zilovertamab vedotin

BIOLOGICAL: Rituximab

DRUG: Gemcitabine

DRUG: Oxaliplatin

DRUG: Bendamustine

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Che...
The safety run-in part of the study aims to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy. The phase 3 part of the study aims to compare event-free survival (EFS) and overall survival (OS) of partici...

DRUG: Blinatumomab

DRUG: Low-intensity chemotherapy regimen

DRUG: SOC chemotherapy regimen

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin...
AB-101 is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that are known to kill cancer cells. This clinical ...

DRUG: AB-101

DRUG: Rituximab

DRUG: Interleukin-2

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Bendamustine

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies

DRUG: Fludarabine

DRUG: Busulfan

DRUG: Melphalan

DRUG: Rituximab

DRUG: Levetiracetam

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia/New Zealand. T...

RADIATION: Involved site radiotherapy

DRUG: Doxorubicin

DRUG: Bleomycin

DRUG: Brentuximab vedotin

DRUG: Vinblastine

DRUG: Dacarbazine

DRUG: Haematopoietic growth factor

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and...
Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease (GVHD) in leukemic an...

DRUG: EAGD T-cell infusion (Phase I)

DRUG: EAGD T-cell infusion (Expansion)

Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)
The purpose of the study is to evaluate the safety and effectiveness of siltuximab for participants being treated for large granular lymphocytic leukemia (LGLL).

DRUG: Siltuximab

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

DRUG: BGB-16673

Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Ce...
This phase II trial studies how well OBI-3424 works in treating patients with T-cell acute lymphoblastic leukemia that has come back (relapsed) or does not response to treatment (refractory). Drugs used in chemotherapy, such as OBI-3424, work in diff...

DRUG: AKR1C3-activated Prodrug OBI-3424

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
Background: Lymphoma is a type of blood cancer. Blood cell transplant can cure some people with lymphoma. Researchers want to see if they can limit the complications transplant can cause. Objective: To test if a stem cell transplant can cure or co...

DRUG: ATL-RIC

DRUG: mRIC

PROCEDURE: allo HCT

DRUG: RIC

DRUG: GVHD prophylaxis

DRUG: IOC

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
The study will measure the safety, tolerability, and efficacy with acalabrutinib in combination with rituximab in treatment-naïve elderly and/or frail patients with diffuse large B-cell lymphoma (DLBCL), who are otherwise unsuitable for standard fron...

DRUG: Acalabrutinib

BIOLOGICAL: Rituximab

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuz...
This is a Phase I/II, multicenter, open-label, dose-escalation study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of a novel T-Cell bispecific (TCB), glofitamab, administered by intravenous (IV) infusion as a sing...

DRUG: Glofitamab

DRUG: Obinutuzumab

DRUG: Tocilizumab

Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
This is an open-label, multicenter, phase I study, which primary objective is to characterize the safety and tolerability of PIT565 and to identify maximal tolerated doses (MTDs) and/or recommended doses (RDs), schedule and route of administration in...

BIOLOGICAL: PIT565

CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted...
The major morbidities of allogeneic hematopoietic stem cell transplant with non-human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life threatening infections. T depletion of the donor hematopoietic stem cell graft is...

DEVICE: CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Depleted Peripheral Stem Cell Addback

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
This phase II trial tests whether loncastuximab tesirine works to shrink tumors in patients with B-cell malignancies that have come back (relapsed) or does not respond to treatment (refractory). Loncastuximab tesirine is a monoclonal antibody, called...

BIOLOGICAL: Loncastuximab Tesirine

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymph...
This phase Ib trial tests the safety and effectiveness of tafasitamab, acalabrutinib, and obinutuzumab in treating patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). CLL and SLL are types of ca...

DRUG: Acalabrutinib

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

PROCEDURE: Echocardiography

BIOLOGICAL: Obinutuzumab

OTHER: Questionnaire Administration

BIOLOGICAL: Tafasitamab

NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large...
This study will evaluate the safety and efficacy of NKTR-255 following CD19-directed chimeric antigen (CAR)-T cell therapy in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL). NKTR-255 is an investigational IL-15 receptor agon...

DRUG: NKTR-255 at 1.5 µg/kg

DRUG: NKTR-255 at 3.0 μg/kg

DRUG: NKTR-255 at 3.0/6.0 μg/kg

OTHER: Placebo Comparator

TTI-622 in Combination with Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large ...
This phase II trial tests the safety, side effects, and best dose of TTI-621 (closed to enrollment) or TTI-622 in combination with pembrolizumab in treating patients with diffuse large B-cell lymphoma that has come back after a period of improvement ...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

DRUG: Ontorpacept

BIOLOGICAL: Pembrolizumab

PROCEDURE: Positron Emission Tomography

DRUG: Maplirpacept

PROCEDURE: Biopsy

Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in ...
This phase II trial tests how well pembrolizumab and tazemetostat work to treat patients who have received autologous stem cell transplantation (ASCT) or chimeric antigen receptor (CAR) T cell therapy for aggressive non hodgkins lymphoma. A monoclona...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

PROCEDURE: Echocardiography

BIOLOGICAL: Pembrolizumab

PROCEDURE: Positron Emission Tomography

DRUG: Tazemetostat

Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hod...
This study is being done to test the safety and effectiveness of pembrolizumab followed by radiation therapy in Hodgkin lymphoma. The purpose of this study is to determine how effective combining the research drug, pembrolizumab, with a targeted for...

DRUG: Pembrolizumab

RADIATION: Involved Site Radiation Therapy

Acalabrutinib with or Without Obinutuzumab in Treating Patients with Early-Stage Chronic Lymphocytic...
This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating patients with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking som...

DRUG: Acalabrutinib

OTHER: Laboratory Biomarker Analysis

BIOLOGICAL: Obinutuzumab

OTHER: Patient Observation

OTHER: Quality-of-Life Assessment

90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation fo...
This phase I trial is to find out the best dose, possible benefits and/or side effects of 90Y-DOTA-anti-CD25 basiliximab given together with fludarabine, melphalan, and total marrow and lymphoid irradiation (TMLI) in treating patients with high-risk ...

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

BIOLOGICAL: Basiliximab

DRUG: Fludarabine Phosphate

DRUG: Indium In 111-DOTA-Basiliximab

DRUG: Melphalan

BIOLOGICAL: Palifermin

RADIATION: Total Lymphoid Irradiation

RADIATION: Total Marrow Irradiation

BIOLOGICAL: Yttrium Y 90 Basiliximab

ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic ...
This phase I/II trial studies the side effects and best dose of ONC201 and to see how well it works in treating patients with acute leukemia or high-risk myelodysplastic syndrome that has returned after a period of improvement (relapsed) or does not ...

DRUG: Akt/ERK Inhibitor ONC201

A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cel...
This study is researching a combination of 2 experimental drugs, referred to as "study drugs", called odronextamab (also known as REGN1979) and cemiplimab (also known as REGN2810). The study is focused on patients who have relapse/refractory aggressi...

DRUG: cemiplimab

DRUG: odronextamab

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Pat...
This phase II trial investigates how well modified VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, and cytarabine hydrochloride) and acalabrutinib as first line therapy work in treating transplant-eligible pati...

DRUG: Acalabrutinib

DRUG: Bortezomib

DRUG: Cyclophosphamide

DRUG: Cytarabine

DRUG: Doxorubicin Hydrochloride

DRUG: Prednisone

BIOLOGICAL: Rituximab

BIOLOGICAL: Rituximab and Hyaluronidase Human

A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)
A Phase 1/2 Study of bbT369, a dual targeting CAR T cell drug product with a gene edit, in Relapsed and/or Refractory B cell Non-Hodgkin's Lymphoma.

BIOLOGICAL: bbT369

A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Di...
The overarching goals of this study are to measure levels of circulating tumor DNA (ctDNA) in patients with early stage diffuse large B cell lymphoma (DLBCL), to assess the change in ctDNA during treatment in order to prospectively identify markers o...

DRUG: Rituximab Prednisone

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Prednisone

CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL
This study will evaluate the safety and tolerability of administering a novel bispecific CD19/CD22-directed CAR T cell product (CD19x22) for the treatment of relapsed or refractory pediatric B-ALL.

BIOLOGICAL: CD19x22 CAR T

CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)
This is an open-label phase I study to determine the safety and recommended phase 2 dose (RP2D) of Senza5 CART5 cells in patients with relapsed or refractory CD5 positive nodal T cell NHL. RP2D will be based on the safety, tolerability, pharmacokinet...

DRUG: Senza5 CART5

CD4CAR for CD4+ Leukemia and Lymphoma
This study is designed as a single arm open label Phase I, 3x3, multicenter study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory T-cell leukemia and lymphoma. Specifically, the study will...

BIOLOGICAL: CD4CAR

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma
This phase II trial studies how well polatuzumab vedotin and combination chemotherapy work in treating patients with previously untreated double, triple hit lymphoma, Double Expressor Lymphoma or High-Grade B Cell Lymphoma. Polatuzumab vedotin is a m...

DRUG: Prednisone

DRUG: Prednisolone

DRUG: Methylprednisolone

BIOLOGICAL: Rituximab

DRUG: Polatuzumab Vedotin

DRUG: Cyclophosphamide

DRUG: Doxorubicin Hydrochloride

First-in-Human (FIH) Trial of 1A46 in Subjects With Advanced CD20 and/or CD19 Positive B-cell Hemato...
This study will evaluate the safety and efficacy of 1A46 in adult patients with advanced CD20 and/or CD19 positive B-cell non-Hodgkin's lymphoma (NHL) or acute lymphoblastic leukemia (ALL).

DRUG: 1A46 Injection

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patient...
The purpose of this Phase 2/3 study is to evaluate efficacy and safety of the combination of selinexor and R-GDP (SR-GDP) in patients with RR DLBCL who are not intended to receive hematopoetic stem cell transplantation (HSCT) or chimeric antigen rece...

DRUG: Selinexor (combination therapy)

DRUG: Selinexor (combination therapy)

DRUG: Selinexor (combination therapy)

DRUG: Placebo matching for Selinexor (combination therapy)

DRUG: Rituximab (combination therapy)

DRUG: Rituximab (combination therapy)

DRUG: Gemcitabine (combination therapy)

DRUG: Dexamethasone (combination therapy)

DRUG: Cisplatin (combination therapy)

DRUG: Selinexor (continuous therapy)

DRUG: Placebo matching for Selinexor (continuous therapy)

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin ...
This phase I trial studies the side effect and best dose of ibrutinib in combination with rituximab, etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride in treating patients with human immunodeficiency virus (H...

DRUG: Cyclophosphamide

DRUG: Doxorubicin Hydrochloride

DRUG: Etoposide

BIOLOGICAL: Filgrastim

DRUG: Ibrutinib

OTHER: Laboratory Biomarker Analysis

BIOLOGICAL: Pegfilgrastim

OTHER: Pharmacological Study

DRUG: Prednisone

BIOLOGICAL: Rituximab

DRUG: Vincristine Sulfate

huCART19-IL18 in CD19+ Cancers
The purpose of this study is to find the maximum dose of huCART19-IL18 cells that is safe for use in humans with CD19+ cancers.

BIOLOGICAL: huCART19-IL18

Study of IMPT-314 in R/R Aggressive B-cell NHL
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of IMPT-314, a bispecific chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive B-cell NHL. Three co...

DRUG: IMPT-314

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematolo...
SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation groups (Group 1 in patients with relapsed/refractory A...

DRUG: SLS009

DRUG: venetoclax

DRUG: azacitidine

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)

BIOLOGICAL: BAFFR-CAR T cells

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.

DRUG: NX-5948

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Be...
One of the ways that cancer grows and spreads is by avoiding the immune system.NK cells are immune cells that kill cancer cells, but are often malfunctioning in people with colorectal cancer and blood cancers. A safe way to give people with colorecta...

DRUG: Vactosertib

DRUG: Fludarabine Phosphate

DRUG: Cyclophosphamide

DRUG: IL-2

DRUG: Natural Killer Cells

A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participan...
The purpose of this study is to characterize safety and to determine the putative recommended Phase 2 dose(s) (RP2D\[s\]), optimal dosing schedule(s) and route(s) of administration of JNJ-80948543 in Part A (Dose Escalation) and to further characteri...

DRUG: JNJ-80948543

Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Dif...
This phase II trial evaluates whether loncastuximab tesirine and rituximab followed by dose-adjusted doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone works to treat patients with high risk diffuse large B-cell lymphoma. Loncastux...

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Etoposide

BIOLOGICAL: Loncastuximab Tesirine

DRUG: Prednisone

BIOLOGICAL: Rituximab

DRUG: Vincristine

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refracto...
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrader (LDD) of BCL6 (BCL6 LDD), as a single agent and...

DRUG: BMS-986458

DRUG: Rituximab

Epcoritamab-CAR T Cells for Large B-cell Lymphomas
This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual lymphoma after CAR T cells, epcoritamab can help to effectively treat that lymphoma.

DRUG: Epcoritamab

PRO1160 for Advanced Solid and Liquid Tumors (PRO1160-001)
Brief Summary: This study will test the safety, including side effects, and determine the characteristics of a drug called PRO1160 in participants with solid tumors. Participants will have solid tumor or liquid cancer that has spread through the bo...

DRUG: PRO1160

Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)
SC262-101 is a Phase 1 study to evaluate SC262 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.

DRUG: SC262

Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
If transplantation using mismatched unrelated donors or non-first-degree relatives could be performed with an acceptable toxicity profile, an important unmet need would be served. Towards this goal, the current study extends our platform of nonmyeloa...

DRUG: Fludarabine

DRUG: Cytoxan

RADIATION: Total Body Irradiation

PROCEDURE: Allogeneic Blood or Marrow Transplant

PROCEDURE: Peripheral Blood Stem Cell Transplant

DRUG: Mycophenolate Mofetil

DRUG: Sirolimus

DRUG: Tacrolimus

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
This research study is studying a combination of drugs as a possible treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The names of the study drugs involved in this study are: * obinutuzumab * venetoclax * acalab...

DRUG: Venetoclax

DRUG: Obinutuzumab

DRUG: Acalabrutinib

Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to C...
This phase II trial tests how well pirtobrutinib (LOXO-305) and venetoclax works in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that remains despite treatment (resistant) with covalent bruton tyrosine...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Pirtobrutinib

DRUG: Venetoclax

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory...
This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL. The study will be conducted in compliance with the International Council on Harmonisati...

DRUG: Fludarabine

DRUG: Cyclophosphamide

DRUG: JCAR017

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
A multi-center, open-label, randomized, phase Ib study to evaluate the pharmacokinetics (PK) of HQP1351 and to determine the recommended phase 2 dose (RP2D) of HQP1351 in subjects with CML chronic phase (CP), accelerated phase (AP), or blast phase (B...

DRUG: Ascentage Pharma HQP1351 bioavailable inhibitor

DRUG: Blinatumomab

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients...
This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously ...

DRUG: Zanubrutinib

BIOLOGICAL: Rituximab

OTHER: Patient Observation

PROCEDURE: Bone Marrow Biopsy

OTHER: Fludeoxyglucose F-18

PROCEDURE: Positron Emission Tomography

PROCEDURE: Computed Tomography

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Esophagogastroduodenoscopy

PROCEDURE: Colonoscopy

PROCEDURE: Biospecimen Collection

OTHER: Questionnaire Administration

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lym...
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.

GENETIC: CB-010

DRUG: Cyclophosphamide

DRUG: Fludarabine

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults ...
The most common types of mature B-cell lymphomas (MBLs) in children are Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). Initial treatment cures 90% - 95% of children with these malignancies, leaving a very small population of relapse...

DRUG: Epcoritamab

Phase 1 Trial of ST-001 NanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).

DRUG: Fenretinide

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma...
A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell lymphoma not ...

DRUG: Soquelitinib

DRUG: Belinostat

DRUG: Pralatrexate

Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Ly...
This phase II trial studies how well obinutuzumab and ibrutinib work as front line therapy in treating patients with indolent non-Hodgkin's lymphoma. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow ...

DRUG: Ibrutinib

BIOLOGICAL: Obinutuzumab

OTHER: Laboratory Biomarker Analysis

A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma
This is a first in human, open-label, dose escalation and expansion Phase 1 study of SIM1811-03 in adult patients with advanced solid tumors and cutaneous T-cell lymphoma. SIM1811-03 is a first-in-class IgG1-based humanized anti-tumor necrosis factor...

DRUG: SIM1811-03

Study of Tazemetostat in Lymphoid Malignancies
Tazemetostat is an oral EZH2 inhibitor which has been FDA approved for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received ...

DRUG: Tazemetostat

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against...
This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study is focused on patients with diffuse large B-cell lymphoma (DLBCL) that have not been treated before (...

DRUG: Odronextamab

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Prednisone/Prednisolone

Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative D...
This study will test polatuzumab vedotin in combination with rituximab in patients with treatment-naïve CD20-positive post-transplant lymphoproliferative disorder (PTLD) based on the established efficacy of polatuzumab vedotin in B-cell lymphomas and...

DRUG: Polatuzumab vedotin

DRUG: Rituximab

DRUG: CHP

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for New...
This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ...

PROCEDURE: Biospecimen Collection

BIOLOGICAL: Blinatumomab

PROCEDURE: Bone Marrow Aspiration and Biopsy

DRUG: Cyclophosphamide

DRUG: Cytarabine

DRUG: Dasatinib

DRUG: Dexamethasone

DRUG: Doxorubicin Hydrochloride

PROCEDURE: Echocardiography

PROCEDURE: Electrocardiography

PROCEDURE: Lumbar Puncture

DRUG: Mesna

DRUG: Methotrexate

PROCEDURE: Multigated Acquisition Scan

DRUG: Ponatinib Hydrochloride

DRUG: Prednisone

DRUG: Vincristine Sulfate

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs f...
This study will combine both T cells and antibodies in order to create a more effective treatment. The treatment tested in this study uses modified T-cells called Autologous T Lymphocyte Chimeric Antigen Receptor (ATLCAR) cells targeted against the k...

DRUG: CAR.k.28

DRUG: Fludarabine

DRUG: Cyclophosphamide

DRUG: Bendamustine

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for childre...

DRUG: Obinutuzumab

DRUG: Liposomal ARA-C

DRUG: Ifosfamide

DRUG: Carboplatin

DRUG: Etoposide

Combination Chemotherapy and Nelarabine in Treating Patients with T-cell Acute Lymphoblastic Leukemi...
This phase II trial studies the side effects and how well combination chemotherapy and nelarabine work in treating patients with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, vinc...

DRUG: Cyclophosphamide

DRUG: Cytarabine

DRUG: Dexamethasone

DRUG: Doxorubicin Hydrochloride

DRUG: Mercaptopurine

DRUG: Methotrexate

DRUG: Nelarabine

DRUG: Pegaspargase

DRUG: Prednisone

DRUG: Venetoclax

DRUG: Vincristine Sulfate

Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
The goal of this clinical trial is to learn about how a combination of tazemetostat and venetoclax in people with relapsed/refractory Non-Hodgkin Lymphoma (R/R NHL). The main questions that this trial aims to answer are what is the best dose of venet...

DRUG: Venetoclax

DRUG: Tazemetostat

Loncastuximab Tesirine in Combination with DA-EPOCH-R in Patients with Previously Untreated Aggressi...
The overarching hypothesis for this study is that a safe and tolerable dose (i.e., the maximum tolerated dose) will be identified for loncastuximab tesirine in combination with dose-adjusted etoposide phosphate, prednisone, vincristine sulfate (Oncov...

DRUG: Etoposide

DRUG: Doxorubicin

DRUG: Cyclophosphamide

DRUG: Rituximab

DRUG: Vincristine

DRUG: Prednisone

DRUG: Loncastuximab Tesirine 0.075 mg/kg by IV

DRUG: Loncastuximab tesirine 0.12 mg/kg by IV

DRUG: Loncastuximab tesirine 0.15 mg/kg by IV

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic ...
This research is being done to investigate the safety and effectiveness of Darzalex Faspro (daratumumab and hyaluronidase-fihj) (a monoclonal antibody that targets plasma cells that make antibodies) and whether it can lower donor specific antibodies ...

DRUG: Darzalex Faspro (Daratumumab and hyaluronidase-fihj)

DEVICE: JH-DSA Semi-Quant Screen and Response Score

CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive No...
The purpose of this research study is to test if a combination treatment of chimeric antigen receptor (CAR) T-cell therapy, Mosunetuzumab, and Polatuzumab Vedotin will result in tumor reduction.

DRUG: Mosunetuzumab

DRUG: Polatuzumab

BIOLOGICAL: CAR-T Cell Therapy

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
The body has different ways of fighting infection and disease. No single way is perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are proteins that protect the body fr...

BIOLOGICAL: ATLCAR.CD30.CCR4 cells

BIOLOGICAL: ALTCAR.CD30 cells

DRUG: Bendamustine

DRUG: Fludarabine

A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangemen...
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-655, determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and ot...

DRUG: NVL-655

Tulmimetostat (CPI-0209) in Patients With Mycosis Fungoides and Sézary Syndrome
The hypotheses of this study are that single agent CPI-0209 will be safe and well tolerated in patients with advanced (stage IB-IVB) mycosis fungoides (MF)/Sézary syndrome (SS) who have had at least one prior systemic therapy, and that in these patie...

DRUG: Tulmimetostat

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relap...
The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as deter...

DRUG: Zanubrutinib

DRUG: Rituximab

DRUG: Lenalidomide

DRUG: Obinutuzumab

A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Hyaluronida...
The primary purpose of the study is to assess the pharmacokinetics (PK) profile of pembrolizumab (MK-3475) following subcutaneous (SC) injection of pembrolizumab coformulated with hyaluronidase (MK-3475A), and to evaluate the objective response rate ...

BIOLOGICAL: Pembrolizumab Coformulated With Hyaluronidase

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infect...
This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem cell donors works to prevent cytomegalovirus (CMV) infection in patients ...

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

PROCEDURE: Biospecimen Collection

DRUG: Granulocyte Colony-Stimulating Factor

DRUG: Hematopoietic Cell Transplantation Conditioning Regimen

BIOLOGICAL: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine

PROCEDURE: Pheresis

DRUG: Placebo Administration

DRUG: Stem Cell Mobilization Therapy

Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute M...
This phase I trial tests the side effects and best dose of total marrow lymphoid irradiation along with chemotherapy, with fludarabine and melphalan, with or without thiotepa, in combination with Orca-T cells for patients with acute myeloid leukemia ...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Dual-Energy Computed Tomography

PROCEDURE: Echocardiography

DRUG: Fludarabine

PROCEDURE: Magnetic Resonance Imaging

DRUG: Melphalan

PROCEDURE: Multigated Acquisition Scan

BIOLOGICAL: Partially Engineered T-regulatory Cell Donor Graft TRGFT-201

DRUG: Tacrolimus

DRUG: Thiotepa

RADIATION: Total Marrow and Lymphoid Irradiation

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
This study has two phases, Phase I and Phase II. The main goal of the Phase I portion of this research study is to see what doses post-transplant inotuzumab ozogamicin can safely be given to subjects without having too many side effects. The Phase I...

DRUG: Inotuzumab Ozogamicin

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MC...
To learn if the chemotherapy-free combination of pirtobrutinib (also called LOXO-305) and rituximab can help provide long term remission in low and intermediate risk MCL.

DRUG: Rituximab

DRUG: Pirtobrutinib

Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
The primary purpose of this study is to determine safety, feasibility, and the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of CD22 Chimeric Antigen Receptor T-Cell Therapy (CART) cells when administered 28 to 42 days after an infusio...

DRUG: CD22CART infusion

DRUG: Tisagenlecleucel

Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Conso...
To learn about the safety of giving the drug brexucabtagene autoleucel to participants with relapsed/refractory B-cell ALL after treatment with inotuzumab ozogamicin, blinatumomab, and either hyper-CVAD or mini-hyper-CVD. Also, to learn if giving bre...

DRUG: Blinatumomab

DRUG: Inotuzumab Ozogamicin

DRUG: Hyper-CVAD

DRUG: Mini-hyper-CVD

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
This is a single arm pilot study for patients with hematologic malignancies receiving unrelated or haploidentical related mobilized peripheral stem cells (PSCs) using the CliniMACS system for alpha/beta T cell depletion plus CD19+ B cell depletion wi...

DEVICE: Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)

Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemo...
This phase II trial compares the combination of inotuzumab ozogamicin and chemotherapy to the usual chemotherapy in treating patients with B-cell acute lymphoblastic leukemia or B-cell lymphoblastic lymphoma. Inotuzumab ozogamicin is a monoclonal ant...

DRUG: Cyclophosphamide

DRUG: Vincristine

DRUG: Dexamethasone

BIOLOGICAL: Inotuzumab Ozogamicin

DRUG: Methotrexate

DRUG: Cytarabine

DRUG: Methylprednisolone

BIOLOGICAL: Rituximab

DRUG: Prednisone

DRUG: Mercaptopurine

DRUG: Doxorubicin

RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose R...
This study is an open-label Phase II trial of non-Hodgkin lymphoma patients receiving initial treatment with the immunomodulatory agent, pembrolizumab, plus low-dose (4 Gy x 5) involved-site radiotherapy. Eligible patients will have r/r disease with ...

DRUG: Pembrolizumab

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ H...
This is a first-in-human phase 1 study of SYNCAR-001 + STK-009 in patients with CD19+ hematologic malignancies.

DRUG: SYNCAR-001

DRUG: STK-009

DRUG: Cyclophosphamide

DRUG: Fludarabine

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
This study will evaluate fixed-duration therapy with pirtobrutinib and obinutuzumab given over 12 cycles (approximately 1 year) as first-line treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL or SLL).

DRUG: Pirtobrutinib

DRUG: Obinutuzumab

Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin ...
To learn if a form of radiation therapy (called ultra-low-dose - total skin electron beam therapy \[ULD-TSEBT\]) in combination with brentuximab vedotin can help to control mycosis fungoides

DRUG: Brentuximab vedotin

Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tc...
This phase I trial tests the safety, side effects, and best dose of intracerebroventricularly (ICV) administered CD19-chimeric antigen receptor (CAR) T cells in treating patients with primary central nervous system (CNS) lymphoma. CAR T cell therapy ...

PROCEDURE: Aspiration

PROCEDURE: Biospecimen Collection

PROCEDURE: Catheterization

BIOLOGICAL: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

DRUG: Fludarabine

PROCEDURE: Leukapheresis

PROCEDURE: Lumbar Puncture

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Positron Emission Tomography

Pembrolizumab, Ibrutinib and Rituximab in PCNSL
This research study is evaluating a combination therapy of 3 drugs as possible treatments for recurrent primary central nervous system lymphoma (PCNSL). The three drugs being used in the study are: * Pembrolizumab (MK3475) * Ibrutinib * Rituximab (...

DRUG: Ibrutinib

DRUG: Pembrolizumab

DRUG: Rituximab

Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Ri...
This phase II trial studies the safety and efficacy of total marrow and lymphoid irradiation (TMLI) in combination with two chemotherapy drugs, etoposide and cyclophosphamide, as a preparative regimen before donor stem cell transplant in treating pat...

DRUG: etoposide

DRUG: cyclophosphamide

RADIATION: total marrow irradiation

PROCEDURE: allogeneic hematopoietic stem cell transplantation

PROCEDURE: allogeneic bone marrow transplantation

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Pos...
This phase Ib/II clinical trial tests the safety, side effects, and effectiveness of mosunetuzumab with chemotherapy for the treatment of patients with untreated, c-Myc rearrangement positive, high grade B cell lymphoma or diffuse large B cell lympho...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration and Biopsy

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

DRUG: Doxorubicin

PROCEDURE: Echocardiography

DRUG: Etoposide

PROCEDURE: Magnetic Resonance Imaging

BIOLOGICAL: Mosunetuzumab

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Positron Emission Tomography

DRUG: Prednisone

DRUG: Vincristine

LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma
The purpose of this study is to test the effects of a drug called Voraxaze when it's routinely given in combination with methotrexate and rituximab, the standard treatment for CNSL.

DRUG: Methotrexate

DRUG: Rituximab

DRUG: leucovorin

DRUG: Glucarpidase

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide fo...
This phase I trial studies the side effects and best dose of mosunetuzumab when given together with polatuzumab vedotin and lenalidomide in treating patients with diffuse large B-cell lymphoma (DLBCL) that has come back after a period of improvement ...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

DRUG: Lenalidomide

BIOLOGICAL: Mosunetuzumab

DRUG: Polatuzumab Vedotin

PROCEDURE: Positron Emission Tomography

Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Autologous Stem Cell Transp...
This is a two-arm, open-label, phase Ib single-site study with expansion cohorts testing the addition of mosunetuzumab to intensive platinum-based salvage chemotherapy in patients with relapsed/refractory aggressive B cell lymphoma intending to pursu...

DRUG: Mosunetuzumab

DRUG: DHAX

DRUG: ICE

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxo...
The purpose of this study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs Pola-R-CHP in participants with previously untreated C...

DRUG: Glofitamab

DRUG: Polatuzumab vedotin

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Prednisone

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cem...
A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy ...

DRUG: ONM-501

DRUG: Cemiplimab

Safety of Myeloablative Conditioning, Orca-T, and Allogeneic, Donor-Derived CD19/CD22-CAR (Chimeric ...
To assess the safety of administering allogenic, donor-derived CD19/CD22-CAR T cells that meet established release specifications in adults with B-cell ALL following a myeloablative conditioning regimen and Orca-T to determine if this will augment gr...

DRUG: Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)

DRUG: Treg CD34+HSPC (Orca-T)

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intrav...
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The purpose of this study is to assess the change in disease activity of epcoritamab when combined with intravenous a...

DRUG: Epcoritamab

DRUG: Cyclophosphamide

DRUG: Rituximab

DRUG: Vincristine

DRUG: Doxorubicin

DRUG: Prednisone

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell ...
This phase II trial studies the side effects of acalabrutinib, obinutuzumab, and glofitamab and how well they work together for treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not re...

DRUG: Acalabrutinib

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

PROCEDURE: Echocardiography

BIOLOGICAL: Glofitamab

PROCEDURE: Multigated Acquisition Scan

BIOLOGICAL: Obinutuzumab

PROCEDURE: Positron Emission Tomography

Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and ...
Subjects on this study have a type of lymph gland cancer called Non-Hodgkin Lymphoma, acute lymphocytic leukemia, or chronic Lymphocytic Leukemia (these diseases will be referred to as "lymphoma" or "leukemia"). The lymphoma or leukemia has come back...

GENETIC: Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells

GENETIC: Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells

To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
Part 1: This is a 5 Arm study primarily to determine the best dose out of the two dose levels of Belinostat and Pralatrexate combined with CHOP/COP in newly diagnosed PTCL patients based on Safety for part 2 study. Part 2 (Efficacy and Safety): This...

DRUG: Belinostat Injection

DRUG: Pralatrexate Injection

DRUG: CHOP

DRUG: COP

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
This is a randomized, open-label study in adult patients who have completed standard first line of therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual d...

GENETIC: cemacabtagene ansegedleucel

BIOLOGICAL: ALLO-647

DRUG: Fludarabine

DRUG: Cyclophosphamide

DEVICE: Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™

Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma ...
This phase II trial studies the effect of brentuximab vedotin and nivolumab in treating patients with classic Hodgkin lymphoma that has come back (relapsed) or does not respond to treatment (refractory) that have been previously treated with brentuxi...

DRUG: Brentuximab Vedotin

PROCEDURE: Hematopoietic Cell Transplantation

BIOLOGICAL: Nivolumab

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
This phase I trial evaluates the side effects and usefulness of axicabtagene clioleucel (a CAR-T therapy) and find out what effect, if any, it has on treating patients with HIV-associated aggressive B-cell non-Hodgkin lymphoma that has come back (rel...

BIOLOGICAL: Axicabtagene Ciloleucel

DRUG: Cyclophosphamide

DRUG: Fludarabine

A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas
ATG-031 study (alias: PERFORM) is a multicenter, open-label, Phase 1 study of ATG-031 in patients with advanced solid tumors or B-NHL. The study design includes a Dose Escalation Phase and a Dose Expansion Phase, and will enroll patients with advance...

DRUG: ATG-031

A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas. CPI-0209 is a small molecule inhibitor of EZH2.

DRUG: CPI-0209

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Tre...
This phase I trial studies the side effects and best dose of lenalidomide when given together with usual combination chemotherapy (etoposide, prednisone, vincristine sulfate \[Oncovin\], cyclophosphamide, and doxorubicin hydrochloride \[hydroxydaunor...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

DRUG: Doxorubicin Hydrochloride

DRUG: Etoposide

DRUG: Lenalidomide

PROCEDURE: Positron Emission Tomography

DRUG: Prednisone

DRUG: Vincristine Sulfate

Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute...
With this research study has following goals * To confirm the highest tolerable dose of palbociclib in combination with chemotherapy is safe and well-tolerated. * To learn more about side effects of palbociclib in combination with chemotherapy; * To...

DRUG: Palbociclib

DRUG: Dexamethasone

DRUG: Bortezomib

DRUG: Doxorubicin

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refra...
This phase I trial tests the safety, side effects, and best dose of genetically engineered cells called EGFRt/19-28z/IL-12 CAR T cells, and to see how they work in treating patients with hematologic malignancies that makes a protein called CD19 (CD19...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

PROCEDURE: Echocardiography

BIOLOGICAL: EGFRt/19-28z/IL-12 CAR T-lymphocytes

DRUG: Fludarabine Phosphate

PROCEDURE: Leukapheresis

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Positron Emission Tomography

Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma
In this research study is looking to see how safe and effective belantamab mafodotin is in relapsed or refractory plasmablastic lymphoma or ALK+ large B-cell lymphoma. * This research study involves the study drug belantamab mafodotin. * Belantamab ...

DRUG: Belantamab Mafodotin

Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome
This phase I trial identifies the best dose, possible benefits, and/or side effects of duvelisib in combination with nivolumab in treating patients with stage IIB-IVB mycosis fungoides and Sezary syndrome. Duvelisib may stop the growth of tumor cells...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

DRUG: Duvelisib

BIOLOGICAL: Nivolumab

PROCEDURE: Positron Emission Tomography

PROCEDURE: Punch Biopsy

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) of bleximenib in phase 1 (Part 1 \[Dose Escalation\] and to determine the safety and tolerability at RP2D in Phase 1 Part 2 (Dose expansion). The purpose of the Pha...

DRUG: Bleximenib

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymp...
This study will assess safety and feasibility of infusing genetically modified autologous T cells transduced to express a chimeric antigen receptor targeting the B cell surface antigen Cluster of Differentiation 19 (CD19)

DRUG: Fludarabine

DRUG: Cyclophosphamide

BIOLOGICAL: anti-CD19 CAR-T cells

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed ...
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, ...

OTHER: Clinical Observation

DRUG: Crizotinib

OTHER: Laboratory Biomarker Analysis

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R...
Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will as...

DRUG: Epcoritamab

DRUG: Prednisone

DRUG: Rituximab

DRUG: Lenalidomide

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Cyclophosphamide

DRUG: Obinutuzumab

DRUG: Bendamustine

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow an...
This phase I trial tests the safety, side effects, best dose, and effectiveness of 225Ac-DOTA-Anti-CD38 daratumumab monoclonal antibody in combination with fludarabine, melphalan and total marrow and lymphoid irradiation (TMLI) as conditioning treatm...

BIOLOGICAL: Actinium Ac 225-DOTA-Daratumumab

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

BIOLOGICAL: Daratumumab

PROCEDURE: Echocardiography

DRUG: Fludarabine

PROCEDURE: Hematopoietic Cell Transplantation

BIOLOGICAL: Indium In 111-DOTA-Daratumumab

DRUG: Melphalan

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Radionuclide Imaging

PROCEDURE: Single Photon Emission Computed Tomography

DRUG: Sirolimus

DRUG: Tacrolimus

RADIATION: Total Marrow and Lymphoid Irradiation

UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
This phase I/II trial will investigate a new CD19 directed CAR-T therapy manufactured locally with the goals to expedite infusion to wider patient inclusion that includes those who were previously excluded, such as pediatric patients with B-cell NHL ...

DRUG: CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells

Dietary and Topical Magnesium Replacement or Supplementation in Patients with Lymphoma
This early phase I trial investigates the effect of dietary and topical magnesium replacement on magnesium blood levels in patients with lymphoma. Magnesium is an element in the body that is important to cell health. The body cannot make magnesium an...

DRUG: Magnesium Chloride-based Lotion

OTHER: Quality-of-Life Assessment

BEHAVIORAL: Special Diet Therapy

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy ...
Researchers are looking for a way to treat classical Hodgkin lymphoma (cHL) that is relapsed (the cancer has come back after treatment) or refractory (current treatment has stopped working to slow or stop cancer growth). Researchers want to learn if ...

BIOLOGICAL: favezelimab/pembrolizumab

DRUG: bendamustine

DRUG: gemcitabine

Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Settin...
This phase II trial studies how well venetoclax and azacitidine work for the treatment of acute myeloid leukemia after stem cell transplantation. Venetoclax may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survi...

DRUG: Azacitidine

DRUG: Venetoclax

TmCD19-IL18 in CD19+ Cancers
This is a Phase I, open-label dose finding study to assess the safety, tolerability, manufacturing feasibility, pharmacokinetics, and preliminary efficacy of TmCD19-IL18 CAR T cells in patients with CD19+ cancers. This study will take place in two pa...

BIOLOGICAL: TmCD19-IL18

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients with Recurrent or Refractory B-Ce...
This phase I trial studies the side effects and best dose of CD19/CD20 chimeric antigen receptor (CAR) T-cells when given together with chemotherapy, and to see how effective they are in treating patients with non-Hodgkin's B-cell lymphoma or chronic...

BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy

DRUG: Cyclophosphamide

DRUG: Fludarabine Phosphate

BIOLOGICAL: Tocilizumab

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in P...
The purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy vs placebo in combination with R-CHOP chemotherapy in ...

DRUG: Golcadomide

DRUG: Placebo

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Prednisone

DALY II USA/ MB-CART2019.1 for DLBCL
DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL) after rece...

BIOLOGICAL: zamtocabtagene autoleucel (MB-CART2019.1)

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Bendamustine

9-ING-41 in Pediatric Patients with Refractory Malignancies.
9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients. This Phase 1 study will study its efficacy in paediatric patients with advanced malignancies.

DRUG: 9-ING-41

DRUG: Irinotecan

DRUG: Temozolomide

DRUG: Cyclophosphamide

DRUG: Topotecan

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
Phase 1 study comprised of open-label, dose escalation and expansion cohort study of P-CD19CD20-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed/refractory B cell malignancies

BIOLOGICAL: P-CD19CD20-ALLO1

DRUG: Rimiducid

Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patie...
This phase I trial studies the side effects and the best dose of intensity modulated total marrow irradiation (IMTMI) when given together with fludarabine phosphate and melphalan in treating patients with cancers of the blood (hematologic) that have ...

DRUG: Fludarabine Phosphate

DRUG: Melphalan

RADIATION: Intensity-Modulated Radiation Therapy

RADIATION: Total Marrow Irradiation

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

PROCEDURE: Peripheral Blood Stem Cell Transplantation

PROCEDURE: Allogeneic Bone Marrow Transplantation

DRUG: Tacrolimus

DRUG: Mycophenolate Mofetil

OTHER: Laboratory Biomarker Analysis

Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
This is a phase 2, single-arm, open-label study to evaluate the safety and efficacy of comprehensive bridging radiation therapy prior to CD19 CAR T-cell therapy for large B-cell lymphoma patients with bulky disease, defined as any lesion ≥5 cm.

RADIATION: Comprehensive Ablative Bridging Irradiation (CABI)

BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy

A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies o...
The primary goal of this Phase 1 study is to characterize the safety and tolerability of DZ-002 and establish the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) of DZ-002 administered on a weekly schedule in patients with solid ...

DRUG: DZ-002

Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients with Relapsed or Refractory Grad...
This phase II trial tests how well mosunetuzumab and polatuzumab vedotin works in treating patients with grade 1-3a follicular lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refra...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

PROCEDURE: Magnetic Resonance Imaging

BIOLOGICAL: Mosunetuzumab

DRUG: Polatuzumab Vedotin

PROCEDURE: Positron Emission Tomography

OTHER: Questionnaire Administration

Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
Subjects have a type of lymph gland disease called Hodgkin or non-Hodgkin Lymphoma or T/NK-lymphoproliferative disease or severe chronic active Epstein Barr Virus (CAEBV) which has come back, is at risk of coming back, or has not gone away after trea...

BIOLOGICAL: EBV-specific T cells: A

BIOLOGICAL: EBV-specific T cells: B

A Phase 1, Study of BMF-500 in Adults With Acute Leukemia
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia.

DRUG: BMF-500

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond to treatme...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspirate

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Echocardiography

DRUG: FACT Complex-targeting Curaxin CBL0137

Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia
This is a Phase I clinical study evaluating the safety and maximum tolerated dose of a novel CAR T-cell product: allogeneic memory (CD45RA- negative) T-cells expressing a CD19-specific CAR 41BBz (CD19-CAR.CD45RA- negative T-cells) for the treatment o...

BIOLOGICAL: CD19-CAR(Mem) T-cells

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Mesna

DEVICE: CliniMACS

PROCEDURE: Leukapheresis

Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant ...
This phase I studies the side effects and best dose of total marrow and lymphoid irradiation when given together with fludarabine and melphalan before donor stem cell transplant in treating participants with high-risk acute leukemia or myelodysplasti...

DRUG: Fludarabine

OTHER: Laboratory Biomarker Analysis

DRUG: Melphalan

RADIATION: Total Marrow Irradiation

Phase 1, Open-label, Dose-escalation Trial with CD38-SADA:177 Lu-DOTA Drug Complex in Subjects with ...
Patients with non-Hodgkin Lymphoma will be treated with CD38-SADA:177Lu-DOTA complex (The IMP is a two-step radioimmunotherapy, delivered as two separate products CD38-SADA and 177Lu-DOTA) to establish optimal and safe therapeutic doses and dosing sc...

DRUG: CD38-SADA:177Lu-DOTA Complex

Pembro Plus CAR T-cell Therapy in R/R in PMBCL
This research study is evaluating the combination of drugs, pembrolizumab with chimeric antigen receptor (CAR) T-cell therapy, as a possible treatment for primary mediastinal B-cell lymphoma that has recurred after prior treatment. The names of the ...

DRUG: Pembrolizumab

DRUG: Lymphodepletion Chemotherapy

DRUG: Chimeric Antigen Receptor (CAR) Therapy Infusion

PROCEDURE: Leukapheresis

VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Le...
This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus carrying the human NIS and IFN beta genes (VSV-hIFNbeta-sodium iodide symporter \[NIS\]) with or without cyclophosphamide or ipilimumab and nivolumab ...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter

PROCEDURE: Single Photon Emission Computed Tomography

BIOLOGICAL: Cemiplimab

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by...

BIOLOGICAL: HSCT with TBI Regimen

BIOLOGICAL: HSCT with Non-TBI Regimen

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
This study aimed to evaluate the efficacy of a novel regimen consisting of polatuzumab vedotin in combination with rituximab, gemcitabine, dexamethasone, and cisplatin (PV-RGDP) for the treatment of diffuse large B-cell lymphoma that either came back...

DRUG: Polatuzumab vedotin (PV)

DRUG: Rituximab

DRUG: Hyaluronidase

DRUG: Gemcitabine

DRUG: Cisplatin

DRUG: Dexamethasone

DRUG: GCSF

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab i...
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purpose of this study is to assess the safety and tolerability of epcoritamab in combination with anti-neoplastic ...

DRUG: Epcoritamab

DRUG: Lenalidomide

DRUG: Ibrutinib

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Doxorubicin Hydrochloride [HCl]

DRUG: Prednisone

DRUG: Polatuzumab Vedotin

DRUG: Venetoclax

DRUG: CC-99282

DRUG: Pirtobrutinib

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic...
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse events (AEs).

DRUG: Ibrutinib

DRUG: Venetoclax

A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma
This is a prospective, open-label, multi-center clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of firicabtagene autoleucel (firi-cel), a CD22-directed autologous Chimeric...

DRUG: Fludarabine (Conditional therapy)

DRUG: Cyclophosphamide Monohydrate (Conditional therapy)

DRUG: firi-cel (Experimental drug)

A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) Patients
The study aims to evaluate the safety, efficacy, and tolerability of subcutaneous (SC) blinatumomab for treatment of Acute Lymphoblastic Leukemia (ALL), to determine the maximum tolerated dose (MTD), and recommended phase 2 dose(s) (RP2D) of SC admin...

DRUG: Blinatumomab

Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leuke...
This phase I/II trial studies the best dose, possible benefits and/or side effects of oral azacitidine in treating patients with T-cell large granular lymphocytic leukemia that has come back (relapsed) or has not responded to previous treatment (refr...

DRUG: Oral Azacitidine

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants...
This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with select relapsed or refractory (R/R) hematologic malignancies. The purpose of this study is to evaluate t...

DRUG: PRT2527

DRUG: Zanubrutinib

DRUG: Venetoclax

A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas
The purpose of this study is to test whether giving acalabrutinib is safe and effective in controlling relapsed central nervous system (CNS) lymphoma. Currently, there are no FDA-approved treatments for relapsed CNS lymphoma. Although acalabrutinib h...

DRUG: Acalabrutinib

DRUG: Isavuconazole

Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leu...
This phase I/II trial studies the side effects and best dose of inotuzumab ozogamicin and to see how well it works when given together with combination chemotherapy in treating patients with acute lymphoblastic leukemia. Inotuzumab ozogamicin is a mo...

BIOLOGICAL: Blinatumomab

DRUG: Cyclophosphamide

DRUG: Cytarabine

DRUG: Dexamethasone

BIOLOGICAL: Inotuzumab Ozogamicin

OTHER: Laboratory Biomarker Analysis

DRUG: Mercaptopurine

DRUG: Methotrexate

DRUG: Prednisone

BIOLOGICAL: Rituximab

DRUG: Vincristine

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas

DRUG: DR-01

Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/...
The purpose of this study is to test any good or bad effects of the study drug called of ibrutinib (also known as Imbruvica™). At this stage of this trial, the study is investigating whether Ibrutinib can be incorporated into the established first-li...

DRUG: Ibrutinib

DRUG: HD- Methotrexate (MTX)

DRUG: Rituximab + HD- Methotrexate (MTX)

DRUG: procarbazine

AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B...
Children, adolescents, and young adults with malignant and non-malignant conditionsundergoing an allogeneic stem cell transplantation (AlloSCT) will have the stem cells selected utilizing α/β CD3+/CD19+ cell depletion. All other treatment is standard...

DRUG: alpha beta depletion

Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethaso...
BACKGROUND: * Primary CNS lymphoma (PCNSL) is a rare subtype of diffuse large B-cell lymphoma. * The outcome for patients with this diagnosis is significantly worse than for that of systemic DLBCL. Most treatment approaches in the past have included...

DRUG: Isavuconazole

DRUG: TEDDI

BIOLOGICAL: Rituximab

DRUG: Cytarabine

DRUG: TEDD

DRUG: Ibrutinib (Arms 2, 3 and 4)

DRUG: Methotrexate

DRUG: Ibrutinib (Arm 1 - Closed with Amendment G)

DRUG: Ibrutinib (Arm 4)

Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
This study involved patients that have a cancer called diffuse large B cell lymphoma (DLBCL), NK and T cell lymphomas (NK/TL) or classical Hodgkin lymphoma (cHL) (hereafter these 3 diseases will be referred to as lymphoma). Patients lymphoma has come...

BIOLOGICAL: CD30.CAR-EBVST cells

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma...
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of oral cemsidomide (also known as CFT7455) administered at different dosages in subjects with Relapsed/Refractory (r/r)...

DRUG: cemsidomide

DRUG: Dexamethasone Oral

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
This is a Phase I/II, interventional, single-arm, open-label, treatment study designed to evaluate the safety and efficacy of Interleukin-7 and Interleukin-15 (IL-7/IL-15) manufactured chimeric antigen receptor (CAR)-20/19-T cells as well as the feas...

BIOLOGICAL: 8/12-Day Production of Car-T Cells

BIOLOGICAL: 8/12-Day Production of Cryopreserved Car-T Cells

BIOLOGICAL: 12-Day Production of Car-T Cells

A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL a...
This is a Phase II single-center open label trial of the combination of ATRA and pembrolizumab treatment in patients with histologically proven, relapsed or refractory Hodgkin Lymphoma or B-Non-Hodgkin-lymphoma.

DRUG: ATRA

DRUG: Pembrolizumab

A Study of NX-1607 in Adults With Advanced Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

DRUG: NX-1607

DRUG: Paclitaxel

CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
The purpose of the study is to evaluate the safety and tolerability of the study drug, calaspargase pegol, when given with multi-agent chemotherapy.

DRUG: Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy)

DRUG: Calaspargase Pegol

DRUG: Rituximab

Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma
Open-label, Phase 1 Study of CD19 t-haNK as a Single Agent and in Combination With an IL-15 Superagonist (N-803) and Rituximab in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma. Up to 20 subjects will be enrolled and randomized 1:1 to 1 of 2 ...

DRUG: N803

BIOLOGICAL: CD19t-haNK suspension

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Rituximab

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
This study is being done to test the effectiveness of zanubrutinib in combination with venetoclax in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

DRUG: Venetoclax

DRUG: Zanubrutinib

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NP...
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL.

DRUG: BMF-219

Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relaps...
This is an open label, non-randomized, phase 1 study of anti-CD19 CAR-T cells against relapsed CD19 positive NHL, CLL and ALL based in a lymphodepletion regimen (fludarabine and cyclophosphamide) and using a CellReGen-based process for manufacturing ...

BIOLOGICAL: Anti-CD19 CAR-T cells

A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Participants With Aggressi...
The study is researching an experimental drug called REGN5837 in combination with another experimental drug, odronextamab. The aim of the study is to see how safe and tolerable the study drugs are, and to define the recommended dose for phase 2 for t...

DRUG: Odronextamab

DRUG: REGN5837

CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First...
This phase I trial tests the safety, side effects, and best dose of autologous anti-CD19 CAR-expressing T lymphocytes (CD19-CAR T cells) in older adults with B-cell acute lymphoblastic leukemia. Chimeric antigen receptor (CAR) T-cell therapy is a typ...

DRUG: Autologous Anti-CD19 CAR-expressing T Lymphocytes

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration and Biopsy

DRUG: Cyclophosphamide

DRUG: Fludarabine

PROCEDURE: Leukapheresis

OTHER: Questionnaire Administration

Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants with Epstein-...
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid...

BIOLOGICAL: tabelecleucel

SynKIR-310 for Relapsed/Refractory B-NHL
This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.

BIOLOGICAL: SynKIR-310

A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymp...
This is a First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas.

DRUG: ATG-101

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R...
Follicular Lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will as...

DRUG: Epcoritamab

DRUG: Rituximab

DRUG: Lenalidomide

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
The purpose of this study is to test whether BV-AVD is an effective treatment in people with early stage, bulky Hodgkin lymphoma that was recently diagnosed and who have not yet received any treatments for their disease. BV is a type of drug called ...

DRUG: Brentuximab vedotin

DRUG: Doxorubicin

DRUG: Vinblastine

DRUG: Dacarbazine

DRUG: Pembrolizumab

DRUG: Gemcitabine

DRUG: Vinorelbine

DIAGNOSTIC_TEST: FDG-PET/CT scan

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-ce...
The goal of this research study is to evaluate the combination of study drugs, Glofitamab and Polatuzumab, and a standard chemotherapy regimen, R-CHP, as a treatment for high-risk diffuse large B-cell lymphoma. The names of the treatment interventio...

DRUG: Glofitamab

DRUG: Polatuzumab

DRUG: Rituximab

DRUG: Doxorubicin Hydrochloride

DRUG: Cyclophosphamide

DRUG: Prednisone

Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKAL...
Patients have a type of cancer called NHL, Multiple Myeloma (MM) or CLL that has come back or has not gone away after treatment. There is no standard treatment for the cancer at this time or the currently used treatments do not work completely in all...

BIOLOGICAL: Kappa CD28 T cells

CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial
This study seeks to investigate an evidence-based, manualized, behavioral health intervention, Cognitive Behavioral Therapy for Insomnia (CBT-I), in individuals with primary brain tumors (PBT) and insomnia. Our project will assess the feasibility and...

BEHAVIORAL: Cognitive Behavioral Therapy for Insomnia

Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patien...
This phase II trial studies how well donor umbilical cord blood transplant with ex-vivo expanded cord blood progenitor cells (dilanubicel) works in treating patients with blood cancer. Before the transplant, patients will receive chemotherapy (fludar...

BIOLOGICAL: Dilanubicel

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Thiotepa

RADIATION: Total-Body Irradiation

PROCEDURE: Umbilical Cord Blood Transplantation

OTHER: Laboratory Biomarker Analysis

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspirate

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Electrocardiography

PROCEDURE: Computed Tomography

Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follic...
This phase II trial studies how well obinutuzumab, ibrutinib, and venetoclax work in treating patients with previously untreated stage II-IV follicular lymphoma. Immunotherapy with obinutuzumab may induce changes in body's immune system and may inter...

DRUG: Ibrutinib

BIOLOGICAL: Obinutuzumab

DRUG: Venetoclax

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
CP-MGD024-01 is a Phase 1, open-label, multi-center study of MGD024 as a single agent in participants with select blood cancers that have not responded to treatment with standard therapies or who have relapsed after treatment. The study is designed t...

DRUG: MGD024

Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Y...
This phase I trial studies the best dose and side effects of CD19/CD22 chimeric antigen receptor (CAR) T cells when given together with chemotherapy, and to see how well they work in treating children or young adults with CD19 positive B acute lympho...

BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy

DRUG: Cyclophosphamide

DRUG: Fludarabine Phosphate

OTHER: Laboratory Biomarker Analysis

OTHER: Questionnaire Administration

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
This is a phase I/II study to evaluate the feasibility, safety and preliminary antitumor efficacy of rapcabtagene autoleucel (also known as YTB323). Rapcabtagene autoleucel will be investigated in combination with ibrutinib in chronic lymphocytic leu...

BIOLOGICAL: Rapcabtagene autoleucel single agent

DRUG: Ibrutinib

Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22 administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of this study is to evaluate the safety and clinical a...

BIOLOGICAL: UCART20x22

BIOLOGICAL: CLLS52

Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma

DRUG: ONO-4685

A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants W...
Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries. The purpose of this study is to assess how well ABBV-453 works adult participants with relapsed/refractory (R/R) untreated CLL/small lymphocytic lymphoma (SLL). Adve...

DRUG: Obinutuzumab

DRUG: ABBV-453

newsletter icon

Get the latest thought leadership on your Lymphoma delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.